Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
24,200 | 2021-02-22 00:00:00 UTC | 3 Stocks to Buy with Dividends Yielding More than 4% | ABBV | https://www.nasdaq.com/articles/3-stocks-to-buy-with-dividends-yielding-more-than-4-2021-02-22 | null | null | Income investors are frustrated by low dividend yields in today's market, but there are still some high yields if you know where to look. With the S&P 500 average yield below 1.6%, many of the usual suspects and Dividend Aristocrats have been bid down by investors desperate for safe cash flow streams. A deep dive and a... | However, AbbVie is bullish about its growth prospects in other categories, including cancer drugs, Skyrizi for plaque psoriasis, Ubrelvy for migraines, and Rinvoq for rheumatoid arthritis. AbbVie AbbVie (NYSE: ABBV) is the seventh-largest branded pharmaceutical maker in the world by revenue, with well-known drugs inclu... | AbbVie AbbVie (NYSE: ABBV) is the seventh-largest branded pharmaceutical maker in the world by revenue, with well-known drugs including Humira, Botox, Venclexta, and Imbruvica in its portfolio. It would seem that this status is in doubt because the market has allowed AbbVie's forward yield to hit 5%, while most of its ... | AbbVie AbbVie (NYSE: ABBV) is the seventh-largest branded pharmaceutical maker in the world by revenue, with well-known drugs including Humira, Botox, Venclexta, and Imbruvica in its portfolio. It would seem that this status is in doubt because the market has allowed AbbVie's forward yield to hit 5%, while most of its ... | It is AbbVie's top-selling product, and its U.S. sales accounted for 35% of the company's total revenue in 2020. AbbVie AbbVie (NYSE: ABBV) is the seventh-largest branded pharmaceutical maker in the world by revenue, with well-known drugs including Humira, Botox, Venclexta, and Imbruvica in its portfolio. It would seem... |
24,201 | 2021-02-21 00:00:00 UTC | Billionaire Ray Dalio Places Bet on 3 “Strong Buy” Stocks | ABBV | https://www.nasdaq.com/articles/billionaire-ray-dalio-places-bet-on-3-strong-buy-stocks-2021-02-21 | null | null | When billionaire financier Ray Dalio makes a move, Wall Street pays attention. Dalio, who got his start working on the floor of the New York Stock Exchange trading commodity futures, founded the world’s largest hedge fund, Bridgewater Associates, in 1975. With the firm managing about $140 billion in global investments ... | (See BLK stock analysis on TipRanks) AbbVie, Inc. (ABBV) AbbVie is a major name in the pharma industry. AbbVie expects that these drugs will ‘fill the gap’ in profits when the Humira patents expire in 2023, with up to $15 billion in sales by 2025. Humira is currently the main driver of AbbVie’s immunology portfolio, an... | (See BLK stock analysis on TipRanks) AbbVie, Inc. (ABBV) AbbVie is a major name in the pharma industry. AbbVie expects that these drugs will ‘fill the gap’ in profits when the Humira patents expire in 2023, with up to $15 billion in sales by 2025. Humira is currently the main driver of AbbVie’s immunology portfolio, an... | (See BLK stock analysis on TipRanks) AbbVie, Inc. (ABBV) AbbVie is a major name in the pharma industry. AbbVie expects that these drugs will ‘fill the gap’ in profits when the Humira patents expire in 2023, with up to $15 billion in sales by 2025. Humira is currently the main driver of AbbVie’s immunology portfolio, an... | Humira is currently the main driver of AbbVie’s immunology portfolio, and provides $19.8 billion of the portfolio’s $22.2 billion in annual revenues, and a significant part of the company’s total sales. (See BLK stock analysis on TipRanks) AbbVie, Inc. (ABBV) AbbVie is a major name in the pharma industry. AbbVie expect... |
24,202 | 2021-02-21 00:00:00 UTC | Is It Too Late to Buy AbbVie Stock? | ABBV | https://www.nasdaq.com/articles/is-it-too-late-to-buy-abbvie-stock-2021-02-21 | null | null | Investors often have reservations about buying stock in a company that's trading at (or near) its all-time highs. And with a bull market that continues to trend upward, this is the dilemma many of us have faced for almost a year now. But there is one stock in particular that I think is cheap, easy to understand, and ca... | But there is one stock in particular that I think is cheap, easy to understand, and capable of rewarding shareholders with ample returns in the future: AbbVie (NYSE: ABBV). AbbVie's front-line products, including Humira (for Crohn's disease and other indications), Skyrizi (for psoriasis), and Rinvoq (for rheumatoid art... | Humira remains AbbVie's best-selling drug, accounting for about $5 billion of the company's $13.8 billion in sales during the fourth quarter of 2020. With the continued success of Humira, Skyrizi, and Rinvoq, I expect Abbvie to grow revenue at 10% annually -- or more -- until at least 2023. But there is one stock in pa... | Fears of Humira's patent expiration are overblown Some investors may be staying away from the stock because of concerns that AbbVie relies too much on its flagship drug, Humira. Humira remains AbbVie's best-selling drug, accounting for about $5 billion of the company's $13.8 billion in sales during the fourth quarter o... | Fears of Humira's patent expiration are overblown Some investors may be staying away from the stock because of concerns that AbbVie relies too much on its flagship drug, Humira. As a whole, AbbVie is much more than Humira. With the continued success of Humira, Skyrizi, and Rinvoq, I expect Abbvie to grow revenue at 10%... |
24,203 | 2021-02-21 00:00:00 UTC | Ready to Supercharge Your Passive Income? 3 Dividend Stocks You Can't Go Wrong With | ABBV | https://www.nasdaq.com/articles/ready-to-supercharge-your-passive-income-3-dividend-stocks-you-cant-go-wrong-with-2021-02 | null | null | Investing in the stock market can help you build long-term wealth, but it can take years or even decades to see substantial returns.
With dividend-paying stocks, however, you'll not only earn long-term returns on your investments, but you'll also receive dividend payments each year or quarter. Every time you receive di... | AbbVie AbbVie (NYSE: ABBV) is a biopharmaceutical company with a strong dividend track record. AbbVie has been a favorite among dividend investors for years, as it's known for its high dividend yield and for increasing its dividend consistently. For this reason, AbbVie is still in a strong position and should continue ... | AbbVie AbbVie (NYSE: ABBV) is a biopharmaceutical company with a strong dividend track record. AbbVie has been a favorite among dividend investors for years, as it's known for its high dividend yield and for increasing its dividend consistently. For this reason, AbbVie is still in a strong position and should continue ... | AbbVie has been a favorite among dividend investors for years, as it's known for its high dividend yield and for increasing its dividend consistently. AbbVie AbbVie (NYSE: ABBV) is a biopharmaceutical company with a strong dividend track record. For this reason, AbbVie is still in a strong position and should continue ... | AbbVie AbbVie (NYSE: ABBV) is a biopharmaceutical company with a strong dividend track record. AbbVie has been a favorite among dividend investors for years, as it's known for its high dividend yield and for increasing its dividend consistently. For this reason, AbbVie is still in a strong position and should continue ... |
24,204 | 2021-02-20 00:00:00 UTC | It's Already Doubled in 2021, and This Healthcare Juggernaut Is Just Getting Started | ABBV | https://www.nasdaq.com/articles/its-already-doubled-in-2021-and-this-healthcare-juggernaut-is-just-getting-started-2021-02 | null | null | Skin cancer detection company Dermtech (NASDAQ: DMTK) has seen a spree of good news lately. The company is reimagining the way skin cancer is detected, using stickers rather than scalpels to remove cells for testing. With several factors pushing the stock to double so far this year, its ascent may be just beginning.
Th... | Lastly, Dermtech has nine partnerships and collaborations ongoing with big names including AbbVie, Johnson & Johnson, AstraZeneca, and L'Oreal. In hopes of expanding the company's relatively small base quickly, management is exploring partnerships on a PLA home collection kit with various entities -- including telemedi... | Lastly, Dermtech has nine partnerships and collaborations ongoing with big names including AbbVie, Johnson & Johnson, AstraZeneca, and L'Oreal. Since then, insurance companies have taken notice, and Dermtech has racked up agreements with Blue Cross and Blue Shield of Texas (and its approximately 6 million covered membe... | Lastly, Dermtech has nine partnerships and collaborations ongoing with big names including AbbVie, Johnson & Johnson, AstraZeneca, and L'Oreal. Such commercial insurance carrier agreements are crucial because they tend to mean higher reimbursement rates for Dermtech and for clinicians performing the procedure -- meanin... | Lastly, Dermtech has nine partnerships and collaborations ongoing with big names including AbbVie, Johnson & Johnson, AstraZeneca, and L'Oreal. It's also more efficient -- for every 25 biopsies performed, only one melanoma will be found, compared with one melanoma for every 2.7 PLA tests. However, it also has more leve... |
24,205 | 2021-02-19 00:00:00 UTC | EOLS Stock: The Big News That Has Evolus Shares Skyrocketing Today | ABBV | https://www.nasdaq.com/articles/eols-stock%3A-the-big-news-that-has-evolus-shares-skyrocketing-today-2021-02-19 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Evolus (NASDAQ:EOLS) stock was on the rise Friday following news that it’s no longer dealing with lawsuits from AbbVie (NYSE:ABBV) and Medytox.
Source: Bukhta Yurii / Shutterstock.com
The legal battle between the companies was over Evolus selling Jeuveau. T... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evolus (NASDAQ:EOLS) stock was on the rise Friday following news that it’s no longer dealing with lawsuits from AbbVie (NYSE:ABBV) and Medytox. The news today is that AbbVie and Medytox are dropping all claims made against Evolus in their lawsuits. To go al... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evolus (NASDAQ:EOLS) stock was on the rise Friday following news that it’s no longer dealing with lawsuits from AbbVie (NYSE:ABBV) and Medytox. The news today is that AbbVie and Medytox are dropping all claims made against Evolus in their lawsuits. To go al... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evolus (NASDAQ:EOLS) stock was on the rise Friday following news that it’s no longer dealing with lawsuits from AbbVie (NYSE:ABBV) and Medytox. The news today is that AbbVie and Medytox are dropping all claims made against Evolus in their lawsuits. To go al... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evolus (NASDAQ:EOLS) stock was on the rise Friday following news that it’s no longer dealing with lawsuits from AbbVie (NYSE:ABBV) and Medytox. The news today is that AbbVie and Medytox are dropping all claims made against Evolus in their lawsuits. To go al... |
24,206 | 2021-02-19 00:00:00 UTC | AbbVie, Evolus, Medytox Agree To Resolve Intellectual Property Litigation | ABBV | https://www.nasdaq.com/articles/abbvie-evolus-medytox-agree-to-resolve-intellectual-property-litigation-2021-02-19 | null | null | (RTTNews) - AbbVie (ABBV), Evolus (EOLS) and Medytox have reached settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission or ITC case regarding the sale of Jeuveau, between the companies. A California court case filed by Medytox against Evolus will b... | (RTTNews) - AbbVie (ABBV), Evolus (EOLS) and Medytox have reached settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission or ITC case regarding the sale of Jeuveau, between the companies. AbbVie and Medytox will receive milestone and royalty payments... | (RTTNews) - AbbVie (ABBV), Evolus (EOLS) and Medytox have reached settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission or ITC case regarding the sale of Jeuveau, between the companies. As per the terms of the settlement, AbbVie and Medytox will re... | (RTTNews) - AbbVie (ABBV), Evolus (EOLS) and Medytox have reached settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission or ITC case regarding the sale of Jeuveau, between the companies. As per the terms of the settlement, AbbVie and Medytox will re... | (RTTNews) - AbbVie (ABBV), Evolus (EOLS) and Medytox have reached settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission or ITC case regarding the sale of Jeuveau, between the companies. As per the terms of the settlement, AbbVie and Medytox will re... |
24,207 | 2021-02-19 00:00:00 UTC | Own Big Stock Winners? Handle Them the Warren Buffett Way | ABBV | https://www.nasdaq.com/articles/own-big-stock-winners-handle-them-the-warren-buffett-way-2021-02-19 | null | null | Many regard Warren Buffett as the greatest investor of all time. The long-term track record of his insurance conglomerate Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) is nearly unparalleled, and few still alive have the breadth of experience that the 90-year-old Omaha native has about all things Wall Street.
Earlier ... | In the third quarter of 2020, he concentrated on pharma stocks like AbbVie and Bristol-Myers Squibb. Below, we'll look more closely at exactly how Buffett has managed his portfolio's biggest stock winner and what it can teach you in handling your own investments. Because the iPhone maker has continued to rise, Buffett'... | In the third quarter of 2020, he concentrated on pharma stocks like AbbVie and Bristol-Myers Squibb. Once again, Berkshire revealed that its biggest holding by far was Apple (NASDAQ: AAPL), but the company made some modest moves in handling what's been a huge winner for the insurance company. By the end of 2019, a furt... | In the third quarter of 2020, he concentrated on pharma stocks like AbbVie and Bristol-Myers Squibb. By the end of 2019, a further combination of rising Apple stock prices and expanded share holdings meant that Buffett held roughly $73 billion in Apple stock. See the 10 stocks *Stock Advisor returns as of November 20, ... | In the third quarter of 2020, he concentrated on pharma stocks like AbbVie and Bristol-Myers Squibb. By the end of the year, Berkshire was down to 887 million shares of Apple stock. How to handle your winners Many individual investors run into the same issues that Buffett has with Apple. |
24,208 | 2021-02-18 00:00:00 UTC | Daily Dividend Report: MTB,SHW,WMT,WCN,HUM,ABBV | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-mtbshwwmtwcnhumabbv-2021-02-18 | null | null | M&T Bank announced that it has declared a quarterly cash dividend of $1.10 per share on its common stock. The dividend will be payable March 31, 2021 to shareholders of record at the close of business on March 1, 2021.
The Board of Directors of Sherwin-Williams today announced a regular quarterly dividend of $1.65 per ... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... |
24,209 | 2021-02-18 00:00:00 UTC | Here Are All 10 Stocks Warren Buffett Has Been Buying | ABBV | https://www.nasdaq.com/articles/here-are-all-10-stocks-warren-buffett-has-been-buying-2021-02-18 | null | null | Warren Buffett and the rest of Berkshire Hathaway's (NYSE: BRK.A)(NYSE: BRK.B) investing team typically don't discuss the stocks they buy and sell, so we have to rely on the quarterly glimpses of the portfolio we get from Berkshire's SEC filings.
Berkshire just posted its most recent 13-F filing, which shows a snapshot... | AbbVie (NYSE: ABBV) 4,268,766 $455 million Merck (NYSE: MRK) 6,294,333 $477 million Bristol Myers Squibb (NYSE: BMY) 3,364,822 $204 million Kroger (NYSE: KR) 8,555,578 $291 million Verizon, in particular, is a rock-solid income stock trading for a reasonable valuation and could have quite a bit of upside potential duri... | AbbVie (NYSE: ABBV) 4,268,766 $455 million Merck (NYSE: MRK) 6,294,333 $477 million Bristol Myers Squibb (NYSE: BMY) 3,364,822 $204 million Kroger (NYSE: KR) 8,555,578 $291 million Apple (NASDAQ: AAPL) 57,160,000 $7.44 billion U.S. Bancorp (NYSE: USB) 823,834 $40 million General Motors (NYSE: GM) 7,500,000 $397 million... | AbbVie (NYSE: ABBV) 4,268,766 $455 million Merck (NYSE: MRK) 6,294,333 $477 million Bristol Myers Squibb (NYSE: BMY) 3,364,822 $204 million Kroger (NYSE: KR) 8,555,578 $291 million Apple (NASDAQ: AAPL) 57,160,000 $7.44 billion U.S. Bancorp (NYSE: USB) 823,834 $40 million General Motors (NYSE: GM) 7,500,000 $397 million... | AbbVie (NYSE: ABBV) 4,268,766 $455 million Merck (NYSE: MRK) 6,294,333 $477 million Bristol Myers Squibb (NYSE: BMY) 3,364,822 $204 million Kroger (NYSE: KR) 8,555,578 $291 million Warren Buffett and the rest of Berkshire Hathaway's (NYSE: BRK.A)(NYSE: BRK.B) investing team typically don't discuss the stocks they buy a... |
24,210 | 2021-02-17 00:00:00 UTC | Here's What Caused Royalty Pharma's Mixed Results in Q4 | ABBV | https://www.nasdaq.com/articles/heres-what-caused-royalty-pharmas-mixed-results-in-q4-2021-02-17 | null | null | Most investors would view Royalty Pharma (NASDAQ: RPRX) as a disappointment. The company conducted its much-heralded initial public offering (IPO) last year. Shares ended 2020 up only 12%, well below the major market indexes. Its stock is in negative territory so far this year.
Royalty Pharma announced its fourth-quart... | Blockbuster cancer drug Imbruvica, which is marketed by AbbVie and Johnson & Johnson, brought in royalties totaling $85 million, up 12% from the prior-year period. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Pfizer, and Vertex Pharmaceuticals. The company gener... | Blockbuster cancer drug Imbruvica, which is marketed by AbbVie and Johnson & Johnson, brought in royalties totaling $85 million, up 12% from the prior-year period. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Pfizer, and Vertex Pharmaceuticals. By the numbers Ro... | Blockbuster cancer drug Imbruvica, which is marketed by AbbVie and Johnson & Johnson, brought in royalties totaling $85 million, up 12% from the prior-year period. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Pfizer, and Vertex Pharmaceuticals. By the numbers Ro... | Blockbuster cancer drug Imbruvica, which is marketed by AbbVie and Johnson & Johnson, brought in royalties totaling $85 million, up 12% from the prior-year period. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Pfizer, and Vertex Pharmaceuticals. By the numbers Ro... |
24,211 | 2021-02-17 00:00:00 UTC | 2 Top Stocks to Buy for a Post-Pandemic World | ABBV | https://www.nasdaq.com/articles/2-top-stocks-to-buy-for-a-post-pandemic-world-2021-02-17 | null | null | The COVID-19 pandemic is still ongoing, but there is a real possibility that we could go back to some semblance of pre-coronavirus life sometime this year. The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization to two vaccines for the SARS-CoV-2 virus, which causes COVID-19. If all goes wel... | The study compared the safety profile of Xeljanz versus that of TNF inhibitors (drugs such as AbbVie's Humira that treat autoimmune disorders) on RA patients who were at least 50 and had at least one additional cardiovascular risk factor. The coronavirus outbreak and the ensuing stay-at-home orders led to reduced acces... | The study compared the safety profile of Xeljanz versus that of TNF inhibitors (drugs such as AbbVie's Humira that treat autoimmune disorders) on RA patients who were at least 50 and had at least one additional cardiovascular risk factor. Merck (NYSE: MRK) and Pfizer (NYSE: PFE) are two pharma giants with a bright futu... | The study compared the safety profile of Xeljanz versus that of TNF inhibitors (drugs such as AbbVie's Humira that treat autoimmune disorders) on RA patients who were at least 50 and had at least one additional cardiovascular risk factor. During its fiscal year 2020, which ended on Dec. 31, Merck's sales were up a meag... | The study compared the safety profile of Xeljanz versus that of TNF inhibitors (drugs such as AbbVie's Humira that treat autoimmune disorders) on RA patients who were at least 50 and had at least one additional cardiovascular risk factor. However, Keytruda sales jumped by 30% year over year to $14.4 billion. Last year,... |
24,212 | 2021-02-17 00:00:00 UTC | 3 Top Healthcare Stocks That Can Make You Richer in 2021 (and Beyond) | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-that-can-make-you-richer-in-2021-and-beyond-2021-02-17 | null | null | The path to wealth is long, but every step in the right direction counts. That's why it's important to pack your portfolio with stocks that have the long-term stability and shareholder returns that you'll need to make consistent progress over time. Don't confuse stability for being boring, though -- it's often the more... | AbbVie Pharma giant AbbVie (NYSE: ABBV) is an excellent option for anyone interested in getting direct financial exposure to the drug development process. AbbVie's lineup includes Humira, which is one of the world's best selling drugs, netting it nearly $20 billion in 2019 alone. That isn't to say that investors will n... | AbbVie Pharma giant AbbVie (NYSE: ABBV) is an excellent option for anyone interested in getting direct financial exposure to the drug development process. AbbVie's lineup includes Humira, which is one of the world's best selling drugs, netting it nearly $20 billion in 2019 alone. That isn't to say that investors will n... | AbbVie Pharma giant AbbVie (NYSE: ABBV) is an excellent option for anyone interested in getting direct financial exposure to the drug development process. AbbVie's lineup includes Humira, which is one of the world's best selling drugs, netting it nearly $20 billion in 2019 alone. That isn't to say that investors will n... | That isn't to say that investors will need to wait for AbbVie's projects to advance before they see the stock grow, though. AbbVie Pharma giant AbbVie (NYSE: ABBV) is an excellent option for anyone interested in getting direct financial exposure to the drug development process. AbbVie's lineup includes Humira, which is... |
24,213 | 2021-02-15 00:00:00 UTC | These 4 Dividend ETFs Are a Retiree's Best Friend | ABBV | https://www.nasdaq.com/articles/these-4-dividend-etfs-are-a-retirees-best-friend-2021-02-15 | null | null | Whoever said that dogs are man's best friend probably wasn't retired. Sure, it's great to have Fido around for company, but he can't pay the bills as well as a dividend ETF can. In this era of low bond yields, dividend ETFs are an increasingly attractive alternative for retirees who need a reliable stream of income to ... | AT&T, AbbVie, Philip Morris, and Verizon are top holdings. In this era of low bond yields, dividend ETFs are an increasingly attractive alternative for retirees who need a reliable stream of income to supplement their Social Security. While all four of the funds on this list incorporate some type of quality screen, onl... | AT&T, AbbVie, Philip Morris, and Verizon are top holdings. Vanguard Dividend Appreciation ETF (NYSEMKT: VIG) VIG tracks the NASDAQ U.S. Dividend Achievers Select Index, which includes companies that have increased their dividend annually for 10 consecutive years (excluding limited partnerships and REITs). 2. iShares Co... | AT&T, AbbVie, Philip Morris, and Verizon are top holdings. Vanguard Dividend Appreciation ETF (NYSEMKT: VIG) VIG tracks the NASDAQ U.S. Dividend Achievers Select Index, which includes companies that have increased their dividend annually for 10 consecutive years (excluding limited partnerships and REITs). 2. iShares Co... | AT&T, AbbVie, Philip Morris, and Verizon are top holdings. You can do that by selecting dividend ETFs that focus on quality as well as yield. These include companies with payout ratios greater than 75% and those in the top decile of dividend yield. |
24,214 | 2021-02-14 00:00:00 UTC | 3 Embarrassingly Cheap Dividend Stocks | ABBV | https://www.nasdaq.com/articles/3-embarrassingly-cheap-dividend-stocks-2021-02-14 | null | null | Keeping track of all the market developments over the past year -- including hot IPOs, surging cryptocurrency prices, and a historic short squeeze that dominated the news -- can be exhausting. Investors who chase those headlines might make some money, but they could also be badly burned.
Before investors chase those sp... | That might seem difficult as the market and many of the stocks in it hover near all-time highs, but Cisco (NASDAQ: CSCO), AbbVie (NYSE: ABBV), and Philip Morris International (NYSE: PM) all easily fit the bill. AbbVie AbbVie struggled over the past few years as its blockbuster arthritis drug Humira, which generated 61%... | That might seem difficult as the market and many of the stocks in it hover near all-time highs, but Cisco (NASDAQ: CSCO), AbbVie (NYSE: ABBV), and Philip Morris International (NYSE: PM) all easily fit the bill. AbbVie AbbVie struggled over the past few years as its blockbuster arthritis drug Humira, which generated 61%... | That might seem difficult as the market and many of the stocks in it hover near all-time highs, but Cisco (NASDAQ: CSCO), AbbVie (NYSE: ABBV), and Philip Morris International (NYSE: PM) all easily fit the bill. AbbVie AbbVie struggled over the past few years as its blockbuster arthritis drug Humira, which generated 61%... | That might seem difficult as the market and many of the stocks in it hover near all-time highs, but Cisco (NASDAQ: CSCO), AbbVie (NYSE: ABBV), and Philip Morris International (NYSE: PM) all easily fit the bill. AbbVie AbbVie struggled over the past few years as its blockbuster arthritis drug Humira, which generated 61%... |
24,215 | 2021-02-12 00:00:00 UTC | 8 Growing Dividend Payers (up to 8.2%) You Can Sit on for Decades | ABBV | https://www.nasdaq.com/articles/8-growing-dividend-payers-up-to-8.2-you-can-sit-on-for-decades-2021-02-12 | null | null | If we learned anything from 2020, it was the value of a few extra rolls of toilet paper. A close second? The reminder about the value of a reliable dividend.
This lesson has been taught over and over. The dot-com bubble. The Great Recession. The "COVID crash." And sure enough, first-level investors don't learn a thing-... | You also have Pfizer (PFE, 4.5%) and AbbVie (ABBV, 4.9%), which are plenty-safe DIVCON 4s and offer more yield. Jefferies provides clients with asset management, brokerage services, financial advisory, it has a research arm, it underwrites IPOs. Riding dividend growers to red-hot total returns is a staple of my investi... | You also have Pfizer (PFE, 4.5%) and AbbVie (ABBV, 4.9%), which are plenty-safe DIVCON 4s and offer more yield. This "dividend health" system examines a broad world of stocks, digging into important payout metrics such as free cash flow generation, earnings growth and even money allocated to buybacks, then it rates sto... | You also have Pfizer (PFE, 4.5%) and AbbVie (ABBV, 4.9%), which are plenty-safe DIVCON 4s and offer more yield. Many 2X, 3X and even 5X and 10X profits are enjoyed over many years as these payouts continually rise, and stocks "chase their dividends higher." This "dividend health" system examines a broad world of stocks... | You also have Pfizer (PFE, 4.5%) and AbbVie (ABBV, 4.9%), which are plenty-safe DIVCON 4s and offer more yield. Many 2X, 3X and even 5X and 10X profits are enjoyed over many years as these payouts continually rise, and stocks "chase their dividends higher." The Insurers: Rising Interest Rate Catalyst DIVCON likes insur... |
24,216 | 2021-02-11 00:00:00 UTC | Implied CURE Analyst Target Price: $90 | ABBV | https://www.nasdaq.com/articles/implied-cure-analyst-target-price%3A-%2490-2021-02-11 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily Healthcare Bull 3X Shares... | Below is a twelve month price history chart comparing the stock performance of BDX, ABBV, and TMO: Combined, BDX, ABBV, and TMO represent 10.43% of the Daily Healthcare Bull 3X Shares ETF. Daily Healthcare Bull 3X Shares ETF CURE $82.04 $90.21 9.96% Becton, Dickinson & Co BDX $252.90 $281.62 11.35% AbbVie Inc ABBV $104... | Three of CURE's underlying holdings with notable upside to their analyst target prices are Becton, Dickinson & Co (Symbol: BDX), AbbVie Inc (Symbol: ABBV), and Thermo Fisher Scientific Inc (Symbol: TMO). Below is a twelve month price history chart comparing the stock performance of BDX, ABBV, and TMO: Combined, BDX, AB... | Similarly, ABBV has 11.00% upside from the recent share price of $104.05 if the average analyst target price of $115.50/share is reached, and analysts on average are expecting TMO to reach a target price of $538.14/share, which is 10.98% above the recent price of $484.88. Three of CURE's underlying holdings with notabl... | Below is a twelve month price history chart comparing the stock performance of BDX, ABBV, and TMO: Combined, BDX, ABBV, and TMO represent 10.43% of the Daily Healthcare Bull 3X Shares ETF. Three of CURE's underlying holdings with notable upside to their analyst target prices are Becton, Dickinson & Co (Symbol: BDX), Ab... |
24,217 | 2021-02-11 00:00:00 UTC | Where to Invest $5,000 Right Now | ABBV | https://www.nasdaq.com/articles/where-to-invest-%245000-right-now-2021-02-11 | null | null | Do you have $5,000 that you can afford to invest right now? One year ago, if you were to invest that much into shares of AbbVie (NYSE: ABBV), FedEx (NYSE: FDX), or Alibaba Group (NYSE: BABA), you would have made at least $1,000 regardless of which stock you chose. And it's not too late to invest in them today.
These bu... | With a portfolio of drugs that now spans immunology, aesthetics, eye care, women's health, and neuroscience, AbbVie has some excellent diversification, making it an ideal stock to hang on to for the long term. And although its current price-to-earnings (P/E) ratio of 37 looks high when compared to the average stock on ... | One year ago, if you were to invest that much into shares of AbbVie (NYSE: ABBV), FedEx (NYSE: FDX), or Alibaba Group (NYSE: BABA), you would have made at least $1,000 regardless of which stock you chose. AbbVie Healthcare is a reliable sector to invest in because many companies, including AbbVie, sell products that ar... | One year ago, if you were to invest that much into shares of AbbVie (NYSE: ABBV), FedEx (NYSE: FDX), or Alibaba Group (NYSE: BABA), you would have made at least $1,000 regardless of which stock you chose. Alibaba makes for a good investment, whether you are looking for a growth stock to add to your portfolio (that isn'... | Alibaba makes for a good investment, whether you are looking for a growth stock to add to your portfolio (that isn't trading at an obscene valuation), or just want to diversify your portfolio and draw on gains made outside of the U.S. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner ha... |
24,218 | 2021-02-10 00:00:00 UTC | Why Editas Medicine Stock Sank Today | ABBV | https://www.nasdaq.com/articles/why-editas-medicine-stock-sank-today-2021-02-10 | null | null | What happened
Shares of Editas Medicine (NASDAQ: EDIT) sank 11.4% as of the market close on Wednesday. The big decline came after AbbVie (NYSE: ABBV) announced a partnership with privately held Caribou Biosciences to develop chimeric antigen receptor T cell (CAR-T) therapies.
So what
Why did AbbVie's deal with Caribou ... | The big decline came after AbbVie (NYSE: ABBV) announced a partnership with privately held Caribou Biosciences to develop chimeric antigen receptor T cell (CAR-T) therapies. So what Why did AbbVie's deal with Caribou cause Editas stock to fall? Some investors appear to be viewing AbbVie's new partnership with Caribou a... | The big decline came after AbbVie (NYSE: ABBV) announced a partnership with privately held Caribou Biosciences to develop chimeric antigen receptor T cell (CAR-T) therapies. So what Why did AbbVie's deal with Caribou cause Editas stock to fall? Some investors appear to be viewing AbbVie's new partnership with Caribou a... | So what Why did AbbVie's deal with Caribou cause Editas stock to fall? See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie and Editas Medicine. The big decline came after AbbVie (NYSE: ABBV) announced a partnership with privately held Caribou Biosciences to develop chim... | So what Why did AbbVie's deal with Caribou cause Editas stock to fall? See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie and Editas Medicine. The big decline came after AbbVie (NYSE: ABBV) announced a partnership with privately held Caribou Biosciences to develop chim... |
24,219 | 2021-02-10 00:00:00 UTC | AbbVie, Caribou Biosciences Ink CAR-T Cell Products License Deal For $40 Mln Upfront Payment | ABBV | https://www.nasdaq.com/articles/abbvie-caribou-biosciences-ink-car-t-cell-products-license-deal-for-%2440-mln-upfront | null | null | (RTTNews) - AbbVie Inc. (ABBV) and Caribou Biosciences, Inc., a clinical-stage CRISPR genome editing biotechnology company, said Wednesday they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics.
Under the multi-year deal, AbbV... | (RTTNews) - AbbVie Inc. (ABBV) and Caribou Biosciences, Inc., a clinical-stage CRISPR genome editing biotechnology company, said Wednesday they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Under the multi-year deal, AbbV... | Under the multi-year deal, AbbVie will utilize Caribou's next-generation Cas12a CRISPR hybrid RNA-DNA (chRDNA) genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies directed to targets specified by AbbVie. AbbVie will have exclusive rights to Caribou's next-generation Cas12a ... | (RTTNews) - AbbVie Inc. (ABBV) and Caribou Biosciences, Inc., a clinical-stage CRISPR genome editing biotechnology company, said Wednesday they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Under the multi-year deal, AbbV... | Under the multi-year deal, AbbVie will utilize Caribou's next-generation Cas12a CRISPR hybrid RNA-DNA (chRDNA) genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies directed to targets specified by AbbVie. Caribou will conduct certain pre-clinical research, development, and m... |
24,220 | 2021-02-07 00:00:00 UTC | 3 Top Dividend Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-to-buy-right-now-2021-02-07 | null | null | Investing in dividend stocks boils down to two steps. First, find stocks that pay attractive dividends. Second, eliminate any stocks lacking the strong underlying businesses needed to ensure the dividends keep coming. It's really that simple.
The main drawback to that two-part method is that you'll still have a lot of ... | AbbVie If you're looking for an attractive dividend stock, AbbVie (NYSE: ABBV) should be really high on your list. Can AbbVie keep its streak of dividend increases going? That almost certainly means the drug's sales will sink and negatively impact AbbVie's finances. | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Innovative Industrial Properties. AbbVie If you're looking for an attractive dividend stock, AbbVie (NYSE: ABBV) should be really high on your list. Can AbbVie keep its streak o... | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Innovative Industrial Properties. AbbVie If you're looking for an attractive dividend stock, AbbVie (NYSE: ABBV) should be really high on your list. Can AbbVie keep its streak o... | AbbVie If you're looking for an attractive dividend stock, AbbVie (NYSE: ABBV) should be really high on your list. The company isn't a Dividend Aristocrat like AbbVie because it's only been in business since 2008 and isn't a member of the S&P 500. Can AbbVie keep its streak of dividend increases going? |
24,221 | 2021-02-04 00:00:00 UTC | AbbVie a Top Ranked SAFE Dividend Stock With 4.9% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-a-top-ranked-safe-dividend-stock-with-4.9-yield-abbv-2021-02-04 | null | null | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.9% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report.
Accor... | Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying h... | AbbVie Inc (Symbol: ABBV) made the "Dividend Channel S.A.F.E. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.99% of the SPDR S&P Divi... | According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.99% of the SPDR S&P Dividend ETF (SDY), which holds $339,891,348 worth of ABBV shares. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E.... | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.99% of the SPDR S&P Dividend ETF (SDY), which holds $339,891,348 worth of ABBV shares.... |
24,222 | 2021-02-03 00:00:00 UTC | EARNINGS SUMMARY: Details of AbbVie Q4 Earnings Report | ABBV | https://www.nasdaq.com/articles/earnings-summary%3A-details-of-abbvie-q4-earnings-report-2021-02-03 | null | null | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV):
-Earnings: $38 million in Q4 vs. $2.8 billion in the same period last year. -EPS: $2.92 in Q4 vs. $2.21 in the same period last year. -Analysts projected $2.85 per share -Revenue: $13.86 billion in Q4 vs. $8.7 billion in the same period last year.
The vie... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $38 million in Q4 vs. $2.8 billion in the same period last year. -Analysts projected $2.85 per share -Revenue: $13.86 billion in Q4 vs. $8.7 billion in the same period last year. The views and opinions expressed herein are the views and opinion... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $38 million in Q4 vs. $2.8 billion in the same period last year. -EPS: $2.92 in Q4 vs. $2.21 in the same period last year. -Analysts projected $2.85 per share -Revenue: $13.86 billion in Q4 vs. $8.7 billion in the same period last year. | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $38 million in Q4 vs. $2.8 billion in the same period last year. -Analysts projected $2.85 per share -Revenue: $13.86 billion in Q4 vs. $8.7 billion in the same period last year. The views and opinions expressed herein are the views and opinion... | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: $38 million in Q4 vs. $2.8 billion in the same period last year. -Analysts projected $2.85 per share -Revenue: $13.86 billion in Q4 vs. $8.7 billion in the same period last year. The views and opinions expressed herein are the views and opinion... |
24,223 | 2021-02-03 00:00:00 UTC | AbbVie (ABBV) Q4 2020 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q4-2020-earnings-call-transcript-2021-02-04 | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q4 2020 Earnings Call
Feb 03, 2021, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning and thank you for standing by. Welcome to the AbbVie fourth-quarter 2020earnings conference call [Operator instr... | AbbVie (NYSE: ABBV) Q4 2020 Earnings Call Feb 03, 2021, 9:00 a.m. Welcome to the AbbVie fourth-quarter 2020earnings conference call [Operator instructions] I would now like to introduce Ms. Liz Shea, vice president of investor relations. AbbVie cautions that these forward-looking statements are subject to risks and unc... | We expect our R&D pipeline advancements to lead to the approval of more than a dozen new products or indications over the next two years, including a total of six additional indications for RINVOQ and SKYRIZI, which will cover all of Humira's major indications plus new significant disease areas, including atopic dermat... | We expect our R&D pipeline advancements to lead to the approval of more than a dozen new products or indications over the next two years, including a total of six additional indications for RINVOQ and SKYRIZI, which will cover all of Humira's major indications plus new significant disease areas, including atopic dermat... | We expect our R&D pipeline advancements to lead to the approval of more than a dozen new products or indications over the next two years, including a total of six additional indications for RINVOQ and SKYRIZI, which will cover all of Humira's major indications plus new significant disease areas, including atopic dermat... |
24,224 | 2021-02-03 00:00:00 UTC | 4 Top Stock Trades for Thursday: AMZN, SPOT, BMY, ABBV | ABBV | https://www.nasdaq.com/articles/4-top-stock-trades-for-thursday%3A-amzn-spot-bmy-abbv-2021-02-03 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Bulls extended the stock market’s gains to a third-consecutive day as the earnings continue to roll in. Now, let’s look at a few top stock trades for Thursday.
Top Stock Trades for Tomorrow No. 1: Amazon (AMZN)
Click to Enlarge
Source: Chart courtesy of T... | Click to Enlarge Source: Chart courtesy of TrendSpider AbbVie (NYSE:ABBV) delivered a top- and bottom-line earnings beat and provided better-than-expected guidance. 4: AbbVie (ABBV) On the date of publication, Bret Kenwell held a long position in ABBV and BMY. | 4: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of TrendSpider AbbVie (NYSE:ABBV) delivered a top- and bottom-line earnings beat and provided better-than-expected guidance. On the date of publication, Bret Kenwell held a long position in ABBV and BMY. | 4: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of TrendSpider AbbVie (NYSE:ABBV) delivered a top- and bottom-line earnings beat and provided better-than-expected guidance. On the date of publication, Bret Kenwell held a long position in ABBV and BMY. | The post 4 Top Stock Trades for Thursday: AMZN, SPOT, BMY, ABBV appeared first on InvestorPlace. 4: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of TrendSpider AbbVie (NYSE:ABBV) delivered a top- and bottom-line earnings beat and provided better-than-expected guidance. |
24,225 | 2021-02-03 00:00:00 UTC | AbbVie Q4 Results Top Estimates; Sees FY21 Profit Above View | ABBV | https://www.nasdaq.com/articles/abbvie-q4-results-top-estimates-sees-fy21-profit-above-view-2021-02-03 | null | null | (RTTNews) - AbbVie Inc. (ABBV) reported that its net earnings attributable to the company for the fourth quarter ended December 31, 2020.dropped to $36 million or $0.01 per share from $2.80 billion or $1.88 per share last year.
The company recorded a $4.7 billion increase in the Skyrizi contingent consideration liabili... | (RTTNews) - AbbVie Inc. (ABBV) reported that its net earnings attributable to the company for the fourth quarter ended December 31, 2020.dropped to $36 million or $0.01 per share from $2.80 billion or $1.88 per share last year. The company recorded a $4.7 billion increase in the Skyrizi contingent consideration liabili... | (RTTNews) - AbbVie Inc. (ABBV) reported that its net earnings attributable to the company for the fourth quarter ended December 31, 2020.dropped to $36 million or $0.01 per share from $2.80 billion or $1.88 per share last year. Worldwide net revenues were $13.858 billion, an increase of 59.2 percent on a reported basis... | (RTTNews) - AbbVie Inc. (ABBV) reported that its net earnings attributable to the company for the fourth quarter ended December 31, 2020.dropped to $36 million or $0.01 per share from $2.80 billion or $1.88 per share last year. Worldwide net revenues were $13.858 billion, an increase of 59.2 percent on a reported basis... | (RTTNews) - AbbVie Inc. (ABBV) reported that its net earnings attributable to the company for the fourth quarter ended December 31, 2020.dropped to $36 million or $0.01 per share from $2.80 billion or $1.88 per share last year. Adjusted earnings per share were $2.92 compared to $2.21 in the previous year. Analysts poll... |
24,226 | 2021-02-03 00:00:00 UTC | Here's Why Investors Liked AbbVie's Q4 Results | ABBV | https://www.nasdaq.com/articles/heres-why-investors-liked-abbvies-q4-results-2021-02-03 | null | null | Shares of AbbVie (NYSE: ABBV) soared 21% in 2020, the stock's best performance since 2017. The big pharma hasn't gotten off to a great start so far in 2021, though, with shares down year to date.
The beginning of a bounce could be underway now, however, for the Dividend Aristocrat. AbbVie announced positive fourth-quar... | Shares of AbbVie (NYSE: ABBV) soared 21% in 2020, the stock's best performance since 2017. AbbVie announced positive fourth-quarter results before the market opened on Wednesday. By the numbers AbbVie announced revenue of $13.9 billion in the fourth quarter, a 59% year-over-year jump. | By the numbers AbbVie announced revenue of $13.9 billion in the fourth quarter, a 59% year-over-year jump. Looking ahead AbbVie anticipates GAAP earnings per share for the full-year 2021 between $6.69 and $6.89. Shares of AbbVie (NYSE: ABBV) soared 21% in 2020, the stock's best performance since 2017. | This was a steep decline from AbbVie's GAAP earnings of $2.8 billion, or $1.88 per share, in the prior-year period. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie. Shares of AbbVie (NYSE: ABBV) soared 21% in 2020, the stock's best performance since 2017. | By the numbers AbbVie announced revenue of $13.9 billion in the fourth quarter, a 59% year-over-year jump. Shares of AbbVie (NYSE: ABBV) soared 21% in 2020, the stock's best performance since 2017. AbbVie announced positive fourth-quarter results before the market opened on Wednesday. |
24,227 | 2021-02-03 00:00:00 UTC | AbbVie’s 4Q Profit Tops Analysts’ Estimates; Shares Gain | ABBV | https://www.nasdaq.com/articles/abbvies-4q-profit-tops-analysts-estimates-shares-gain-2021-02-03 | null | null | AbbVie reported 4Q diluted EPS of $2.92, which came in ahead of analysts’ estimates of $2.86. Revenues in the fourth quarter were up by 59.2% year-on-year to $13.8 billion versus analysts’ estimates of $13.7 billion. Shares of the pharma company rose 1.4% in US morning trading.
AbbVie’s (ABBV) CEO Richard A. Gonzalez s... | AbbVie’s (ABBV) CEO Richard A. Gonzalez said, "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the challenges presented by the global pandemic. Divan wrote in a note to investors, “The beat was led by several important products, including S... | AbbVie reported 4Q diluted EPS of $2.92, which came in ahead of analysts’ estimates of $2.86. AbbVie’s (ABBV) CEO Richard A. Gonzalez said, "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the challenges presented by the global pandemic. (S... | (See AbbVie stock analysis on TipRanks) The company provided FY21 diluted EPS guidance in the range of $6.69 to $6.89 and expects its adjusted diluted EPS to be in the range of $12.32 to $12.52. Divan wrote in a note to investors, “The beat was led by several important products, including Skyrizi, Rinvoq, Ubrelvy, Boto... | AbbVie reported 4Q diluted EPS of $2.92, which came in ahead of analysts’ estimates of $2.86. AbbVie’s (ABBV) CEO Richard A. Gonzalez said, "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the challenges presented by the global pandemic. (S... |
24,228 | 2021-02-03 00:00:00 UTC | Should Investors Be Watching These Top Biotech Stocks This Month? | ABBV | https://www.nasdaq.com/articles/should-investors-be-watching-these-top-biotech-stocks-this-month-2021-02-03 | null | null | Are These The Best Biotech Stocks To Buy Now? 4 Names To Know
Biotech stocks have been on fire in the last few months. The reason being how some of these companies delivered on investor expectations by announcing breakthrough clinical results or introduced revolutionary medicine. For instance, biotech companies like Mo... | Top Biotech Stocks To Watch Cassava Sciences Inc. (NASDAQ: SAVA) Jazz Pharmaceuticals (NASDAQ: JAZZ) AbbVie Inc. (NYSE: ABBV) Veracyte Inc. (NASDAQ: VCYT) Cassava Sciences Inc. Cassava is a biotech company that focuses on neuroscience. AbbVie Inc. AbbVie is a biotech company that operates as a research-based pharmaceut... | Top Biotech Stocks To Watch Cassava Sciences Inc. (NASDAQ: SAVA) Jazz Pharmaceuticals (NASDAQ: JAZZ) AbbVie Inc. (NYSE: ABBV) Veracyte Inc. (NASDAQ: VCYT) Cassava Sciences Inc. Cassava is a biotech company that focuses on neuroscience. AbbVie Inc. AbbVie is a biotech company that operates as a research-based pharmaceut... | Top Biotech Stocks To Watch Cassava Sciences Inc. (NASDAQ: SAVA) Jazz Pharmaceuticals (NASDAQ: JAZZ) AbbVie Inc. (NYSE: ABBV) Veracyte Inc. (NASDAQ: VCYT) Cassava Sciences Inc. Cassava is a biotech company that focuses on neuroscience. AbbVie Inc. AbbVie is a biotech company that operates as a research-based pharmaceut... | Top Biotech Stocks To Watch Cassava Sciences Inc. (NASDAQ: SAVA) Jazz Pharmaceuticals (NASDAQ: JAZZ) AbbVie Inc. (NYSE: ABBV) Veracyte Inc. (NASDAQ: VCYT) Cassava Sciences Inc. Cassava is a biotech company that focuses on neuroscience. AbbVie Inc. AbbVie is a biotech company that operates as a research-based pharmaceut... |
24,229 | 2021-02-03 00:00:00 UTC | AbbVie profit beats expectations on Humira demand | ABBV | https://www.nasdaq.com/articles/abbvie-profit-beats-expectations-on-humira-demand-2021-02-03 | null | null | Adds details on botox sales, profit estimates, share movement
Feb 3 (Reuters) - AbbVie Inc ABBV.N forecast annual profit above expectations and beat quarterly estimates on Wednesday on higher demand for its blockbuster drug Humira as well as newer treatments for psoriasis and rheumatoid arthritis, sending its shares up... | Adds details on botox sales, profit estimates, share movement Feb 3 (Reuters) - AbbVie Inc ABBV.N forecast annual profit above expectations and beat quarterly estimates on Wednesday on higher demand for its blockbuster drug Humira as well as newer treatments for psoriasis and rheumatoid arthritis, sending its shares up... | Adds details on botox sales, profit estimates, share movement Feb 3 (Reuters) - AbbVie Inc ABBV.N forecast annual profit above expectations and beat quarterly estimates on Wednesday on higher demand for its blockbuster drug Humira as well as newer treatments for psoriasis and rheumatoid arthritis, sending its shares up... | Adds details on botox sales, profit estimates, share movement Feb 3 (Reuters) - AbbVie Inc ABBV.N forecast annual profit above expectations and beat quarterly estimates on Wednesday on higher demand for its blockbuster drug Humira as well as newer treatments for psoriasis and rheumatoid arthritis, sending its shares up... | Adds details on botox sales, profit estimates, share movement Feb 3 (Reuters) - AbbVie Inc ABBV.N forecast annual profit above expectations and beat quarterly estimates on Wednesday on higher demand for its blockbuster drug Humira as well as newer treatments for psoriasis and rheumatoid arthritis, sending its shares up... |
24,230 | 2021-02-03 00:00:00 UTC | AbbVie Q4 20 Earnings Conference Call At 9:00 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-q4-20-earnings-conference-call-at-9%3A00-am-et-2021-02-03 | null | null | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 3, 2021, to discuss its Q4 20 earnings result.
To access the live webcast, log on at https://investors.abbvie.com/
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasd... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 3, 2021, to discuss its Q4 20 earnings result. To access the live webcast, log on at https://investors.abbvie.com/ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasd... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 3, 2021, to discuss its Q4 20 earnings result. To access the live webcast, log on at https://investors.abbvie.com/ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasd... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 3, 2021, to discuss its Q4 20 earnings result. To access the live webcast, log on at https://investors.abbvie.com/ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasd... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 3, 2021, to discuss its Q4 20 earnings result. To access the live webcast, log on at https://investors.abbvie.com/ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasd... |
24,231 | 2021-02-03 00:00:00 UTC | Merck Q4 Earnings Preview: Keytruda And Gardasil In Focus | ABBV | https://www.nasdaq.com/articles/merck-q4-earnings-preview%3A-keytruda-and-gardasil-in-focus-2021-02-04 | null | null | Merck (NYSE: MRK) is scheduled to report its Q4 2020 results on Thursday, February 4. We expect the company to likely post revenue slightly below and earnings in-line with the consensus estimates, partly due to lower expected sales of vaccines, such as Gardasil and Proquad. That said, Merck should see an overall pickup... | That said, Merck should see an overall pickup in demand due to an increase in hospital visits with economies opening up gradually. While Merck may report earnings slightly below the consensus estimates, our forecast indicates that its valuation is around $102 per share, which is 30% above the current market price of ar... | We expect the company to likely post revenue slightly below and earnings in-line with the consensus estimates, partly due to lower expected sales of vaccines, such as Gardasil and Proquad. (1) Revenues expected to be slightly below the consensus estimates Trefis estimates Merck’s Q4 2020 revenues to be around $12.5 bil... | (1) Revenues expected to be slightly below the consensus estimates Trefis estimates Merck’s Q4 2020 revenues to be around $12.5 billion, slightly below the $12.7 billion consensus estimate. 2) EPS likely to be in-line with the consensus estimates Merck’s Q4 2020 adjusted earnings per share (EPS) is expected to be $1.38... | We expect the company to likely post revenue slightly below and earnings in-line with the consensus estimates, partly due to lower expected sales of vaccines, such as Gardasil and Proquad. (1) Revenues expected to be slightly below the consensus estimates Trefis estimates Merck’s Q4 2020 revenues to be around $12.5 bil... |
24,232 | 2021-02-03 00:00:00 UTC | AbbVie revenue beats expectations on Humira demand | ABBV | https://www.nasdaq.com/articles/abbvie-revenue-beats-expectations-on-humira-demand-2021-02-03 | null | null | Feb 3 (Reuters) - AbbVie Inc ABBV.N beat quarterly revenue estimates and forecast annual profit above expectations on Wednesday due to higher demand for its blockbuster drug Humira as well as newer treatments for psoriasis and rheumatoid arthritis.
AbbVie is betting on the new treatments and wrinkle injection Botox, ac... | Feb 3 (Reuters) - AbbVie Inc ABBV.N beat quarterly revenue estimates and forecast annual profit above expectations on Wednesday due to higher demand for its blockbuster drug Humira as well as newer treatments for psoriasis and rheumatoid arthritis. AbbVie is betting on the new treatments and wrinkle injection Botox, ac... | Feb 3 (Reuters) - AbbVie Inc ABBV.N beat quarterly revenue estimates and forecast annual profit above expectations on Wednesday due to higher demand for its blockbuster drug Humira as well as newer treatments for psoriasis and rheumatoid arthritis. AbbVie is betting on the new treatments and wrinkle injection Botox, ac... | Feb 3 (Reuters) - AbbVie Inc ABBV.N beat quarterly revenue estimates and forecast annual profit above expectations on Wednesday due to higher demand for its blockbuster drug Humira as well as newer treatments for psoriasis and rheumatoid arthritis. AbbVie is betting on the new treatments and wrinkle injection Botox, ac... | Feb 3 (Reuters) - AbbVie Inc ABBV.N beat quarterly revenue estimates and forecast annual profit above expectations on Wednesday due to higher demand for its blockbuster drug Humira as well as newer treatments for psoriasis and rheumatoid arthritis. AbbVie is betting on the new treatments and wrinkle injection Botox, ac... |
24,233 | 2021-02-03 00:00:00 UTC | AbbVie a Top Socially Responsible Dividend Stock With 5.0% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-a-top-socially-responsible-dividend-stock-with-5.0-yield-abbv-2021-02-03 | null | null | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... |
24,234 | 2021-02-02 00:00:00 UTC | Pre-Market Earnings Report for February 3, 2021 : ABBV, SPOT, BSX, HUM, EPD, BIIB, APTV, GWW, CHKP, CNHI, BIP, AVY | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-february-3-2021-%3A-abbv-spot-bsx-hum-epd-biib-aptv-gww-chkp | null | null | The following companies are expected to report earnings prior to market open on 02/03/2021. Visit our Earnings Calendar for a full list of expected earnings releases.
AbbVie Inc. (ABBV) is reporting for the quarter ending December 31, 2020. The large cap pharmaceutical company's consensus earnings per share forecast f... | AbbVie Inc. (ABBV) is reporting for the quarter ending December 31, 2020. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.76 vs. an industry ratio of 14.80. | AbbVie Inc. (ABBV) is reporting for the quarter ending December 31, 2020. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.76 vs. an industry ratio of 14.80. | AbbVie Inc. (ABBV) is reporting for the quarter ending December 31, 2020. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.76 vs. an industry ratio of 14.80. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. (ABBV) is reporting for the quarter ending December 31, 2020. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.76 vs. an industry ratio of 14.80. |
24,235 | 2021-02-02 00:00:00 UTC | Noteworthy Tuesday Option Activity: EA, ABBV, LCI | ABBV | https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-ea-abbv-lci-2021-02-02 | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Electronic Arts, Inc. (Symbol: EA), where a total volume of 19,472 contracts has been traded thus far today, a contract volume which is representative of approximately 1.9 million underlying shares (giv... | Especially high volume was seen for the $110 strike call option expiring February 19, 2021, with 5,174 contracts trading so far today, representing approximately 517,400 underlying shares of ABBV. Below is a chart showing EA's trailing twelve month trading history, with the $165 strike highlighted in orange: AbbVie Inc... | Below is a chart showing EA's trailing twelve month trading history, with the $165 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 45,572 contracts, representing approximately 4.6 million underlying shares or approximately 58.7% of ABBV's average daily trading volume over the past ... | Below is a chart showing EA's trailing twelve month trading history, with the $165 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 45,572 contracts, representing approximately 4.6 million underlying shares or approximately 58.7% of ABBV's average daily trading volume over the past ... | Below is a chart showing EA's trailing twelve month trading history, with the $165 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 45,572 contracts, representing approximately 4.6 million underlying shares or approximately 58.7% of ABBV's average daily trading volume over the past ... |
24,236 | 2021-02-02 00:00:00 UTC | 3 Top Dividend Stocks With Yields Over 4% | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-with-yields-over-4-2021-02-02 | null | null | When it comes to buying stocks, dividends are icing on the cake. Whatever your personal style of stock trading may be, incorporating dividend-paying companies into your portfolio is one of the most effective strategies to maximize your long-term returns and generate consistent cash as an investor.
However, as ill econo... | With its portfolio of best-selling medicines, strong pipeline, and oh-so-juicy dividend, AbbVie is one of the top stocks for long-term investors to buy in today's healthcare landscape. AbbVie Biopharmaceutical behemoth AbbVie (NYSE: ABBV) pays a dividend that yields just shy of 5% based on current share prices. AbbVie ... | AbbVie Biopharmaceutical behemoth AbbVie (NYSE: ABBV) pays a dividend that yields just shy of 5% based on current share prices. AbbVie is a Dividend Aristocrat, having raised its dividend every year for more than 40 years. AbbVie's stellar portfolio of medicines stretches across a range of disciplines, from immunology ... | Bear in mind, AbbVie's total net revenues across all of its medicines came to $32 billion during that nine-month period, meaning that Humira currently generates about half of all the company's revenues. AbbVie Biopharmaceutical behemoth AbbVie (NYSE: ABBV) pays a dividend that yields just shy of 5% based on current sha... | AbbVie is a Dividend Aristocrat, having raised its dividend every year for more than 40 years. AbbVie Biopharmaceutical behemoth AbbVie (NYSE: ABBV) pays a dividend that yields just shy of 5% based on current share prices. AbbVie's stellar portfolio of medicines stretches across a range of disciplines, from immunology ... |
24,237 | 2021-02-02 00:00:00 UTC | 7 Pharmaceutical Stocks With Compelling Pipelines | ABBV | https://www.nasdaq.com/articles/7-pharmaceutical-stocks-with-compelling-pipelines-2021-02-02 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In the last year, pharmaceutical stocks, in general, have taken a back seat to coronavirus vaccine makers. Seemingly, unless it was tackling Covid-19, a drug maker was viewed by stock market traders as dull.
When the market prices future earnings, they bid ... | 7 Blue Chip Stocks to Help Prepare For Your Retirement There are seven pharmaceutical stocks that investors should consider: AbbVie (NYSE:ABBV) AstraZeneca (NASDAQ:AZN) Bristol-Myers Squibb (NYSE:BMY) Gilead Sciences (NASDAQ:GILD) Merck & Co (NYSE:MRK) Pfizer (NYSE:PFE) Viatris (NASDAQ:VTRS) Taken from Stock Rover, not... | 7 Blue Chip Stocks to Help Prepare For Your Retirement There are seven pharmaceutical stocks that investors should consider: AbbVie (NYSE:ABBV) AstraZeneca (NASDAQ:AZN) Bristol-Myers Squibb (NYSE:BMY) Gilead Sciences (NASDAQ:GILD) Merck & Co (NYSE:MRK) Pfizer (NYSE:PFE) Viatris (NASDAQ:VTRS) Taken from Stock Rover, not... | 7 Blue Chip Stocks to Help Prepare For Your Retirement There are seven pharmaceutical stocks that investors should consider: AbbVie (NYSE:ABBV) AstraZeneca (NASDAQ:AZN) Bristol-Myers Squibb (NYSE:BMY) Gilead Sciences (NASDAQ:GILD) Merck & Co (NYSE:MRK) Pfizer (NYSE:PFE) Viatris (NASDAQ:VTRS) Taken from Stock Rover, not... | 7 Blue Chip Stocks to Help Prepare For Your Retirement There are seven pharmaceutical stocks that investors should consider: AbbVie (NYSE:ABBV) AstraZeneca (NASDAQ:AZN) Bristol-Myers Squibb (NYSE:BMY) Gilead Sciences (NASDAQ:GILD) Merck & Co (NYSE:MRK) Pfizer (NYSE:PFE) Viatris (NASDAQ:VTRS) Taken from Stock Rover, not... |
24,238 | 2021-02-01 00:00:00 UTC | Best Biotech Stocks To Buy Right Now? 4 Reporting Earnings This Week | ABBV | https://www.nasdaq.com/articles/best-biotech-stocks-to-buy-right-now-4-reporting-earnings-this-week-2021-02-01 | null | null | Looking For The Top Biotech Stocks To Buy In February?
Any investors worth their salt can tell you that biotech stocks are among the top performers on the stock market today. Whether it is explosive gains within a day or long-term gains, the industry has benefitted investors. Right now, as we enter another intense earn... | Top Biotech Stocks To Buy [Or Sell] This Week Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Bio-Techne Corporation (NASDAQ: TECH) PerkinElmer Inc. (NYSE: PKI) AbbVie Inc. (NYSE: ABBV) Vertex Pharmaceuticals Inc. First up is global biotech firm Vertex. AbbVie Inc. Last but not least, we have biopharmaceutical titan AbbVie.... | Top Biotech Stocks To Buy [Or Sell] This Week Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Bio-Techne Corporation (NASDAQ: TECH) PerkinElmer Inc. (NYSE: PKI) AbbVie Inc. (NYSE: ABBV) Vertex Pharmaceuticals Inc. First up is global biotech firm Vertex. AbbVie Inc. Last but not least, we have biopharmaceutical titan AbbVie.... | Top Biotech Stocks To Buy [Or Sell] This Week Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Bio-Techne Corporation (NASDAQ: TECH) PerkinElmer Inc. (NYSE: PKI) AbbVie Inc. (NYSE: ABBV) Vertex Pharmaceuticals Inc. First up is global biotech firm Vertex. AbbVie Inc. Last but not least, we have biopharmaceutical titan AbbVie.... | Top Biotech Stocks To Buy [Or Sell] This Week Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Bio-Techne Corporation (NASDAQ: TECH) PerkinElmer Inc. (NYSE: PKI) AbbVie Inc. (NYSE: ABBV) Vertex Pharmaceuticals Inc. First up is global biotech firm Vertex. AbbVie Inc. Last but not least, we have biopharmaceutical titan AbbVie.... |
24,239 | 2021-01-31 00:00:00 UTC | These Dividend Stocks Are Practically Money Machines | ABBV | https://www.nasdaq.com/articles/these-dividend-stocks-are-practically-money-machines-2021-01-31 | null | null | If you depend on stocks to generate income, you want the dividend payments to be like clockwork. That requires the underlying businesses to be solid and reliable.
Of course, you'd also like to see those dividends increase over time. Otherwise, inflation could chip away at the amount of money you make and potentially lo... | AbbVie AbbVie (NYSE: ABBV) pays a dividend that I think any income investor would love. AbbVie has increased its dividend payout for 49 consecutive years and is knocking at the door of becoming a Dividend King (S&P 500 members with at least 50 years in a row of dividend hikes). My view is that AbbVie's underlying busin... | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, and Innovative Industrial Properties. AbbVie AbbVie (NYSE: ABBV) pays a dividend that I think any income investor would love. AbbVie has increased its div... | AbbVie has increased its dividend payout for 49 consecutive years and is knocking at the door of becoming a Dividend King (S&P 500 members with at least 50 years in a row of dividend hikes). See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure,... | AbbVie has increased its dividend payout for 49 consecutive years and is knocking at the door of becoming a Dividend King (S&P 500 members with at least 50 years in a row of dividend hikes). See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure,... |
24,240 | 2021-01-29 00:00:00 UTC | 3 Dividend Stocks That Could Pay You for the Rest of Your Life | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-could-pay-you-for-the-rest-of-your-life-2021-01-29 | null | null | Never say never. Plenty of companies that were once seen as permanent pillars of their respective industries are now all but gone, as are their dividends. Blockbuster Video, Eastman Kodak, and J.C. Penney are some of these names that come to mind, and they're just a sampling of the stocks that were once income stalwart... | In fact, the company owns the immunosuppressives Remicade and Stelara, and co-owns leukemia drug Imbruvica with AbbVie, all three of which rank among the world's best-selling drugs. Blockbuster Video, Eastman Kodak, and J.C. Penney are some of these names that come to mind, and they're just a sampling of the stocks tha... | In fact, the company owns the immunosuppressives Remicade and Stelara, and co-owns leukemia drug Imbruvica with AbbVie, all three of which rank among the world's best-selling drugs. Among the most malleable businesses that income-minded investors may want to keep in their portfolios for decades are Johnson & Johnson (N... | In fact, the company owns the immunosuppressives Remicade and Stelara, and co-owns leukemia drug Imbruvica with AbbVie, all three of which rank among the world's best-selling drugs. Among the most malleable businesses that income-minded investors may want to keep in their portfolios for decades are Johnson & Johnson (N... | In fact, the company owns the immunosuppressives Remicade and Stelara, and co-owns leukemia drug Imbruvica with AbbVie, all three of which rank among the world's best-selling drugs. These headwinds, however, don't pose a real threat to the company's dividend or the growth of the payout. The only risk to this business w... |
24,241 | 2021-01-28 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-2021-01-28 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Get the latest Zacks research report on ABBV — FREE Get the latest Zacks research report on BDX — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Brown & Brown Inc (Symbol: BRO) $44.08 $50... | Brown & Brown Inc (Symbol: BRO) $44.08 $50.00 13.43% Brady Corp (Symbol: BRC) $47.14 $52.75 11.90% Carlisle Companies Inc. (Symbol: CSL) $145.69 $163.00 11.88% AbbVie Inc (Symbol: ABBV) $102.79 $114.38 11.27% Becton, Dickinson & Co (Symbol: BDX) $250.89 $277.77 10.71% The average 12-month analyst targets are only targe... | Brown & Brown Inc (Symbol: BRO) $44.08 $50.00 13.43% Brady Corp (Symbol: BRC) $47.14 $52.75 11.90% Carlisle Companies Inc. (Symbol: CSL) $145.69 $163.00 11.88% AbbVie Inc (Symbol: ABBV) $102.79 $114.38 11.27% Becton, Dickinson & Co (Symbol: BDX) $250.89 $277.77 10.71% The average 12-month analyst targets are only targe... | Brown & Brown Inc (Symbol: BRO) $44.08 $50.00 13.43% Brady Corp (Symbol: BRC) $47.14 $52.75 11.90% Carlisle Companies Inc. (Symbol: CSL) $145.69 $163.00 11.88% AbbVie Inc (Symbol: ABBV) $102.79 $114.38 11.27% Becton, Dickinson & Co (Symbol: BDX) $250.89 $277.77 10.71% The average 12-month analyst targets are only targe... |
24,242 | 2021-01-27 00:00:00 UTC | Wednesday Sector Laggards: Materials, Healthcare | ABBV | https://www.nasdaq.com/articles/wednesday-sector-laggards%3A-materials-healthcare-2021-01-27 | null | null | Looking at the sectors faring worst as of midday Wednesday, shares of Materials companies are underperforming other sectors, showing a 2.2% loss. Within that group, Howmet Aerospace Inc (Symbol: HWM) and Linde plc (Symbol: LIN) are two of the day's laggards, showing a loss of 4.6% and 3.9%, respectively. Among the high... | Combined, REGN and ABBV make up approximately 5.5% of the underlying holdings of XLV. Among large Healthcare stocks, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) and AbbVie Inc (Symbol: ABBV) are the most notable, showing a loss of 5.0% and 4.7%, respectively. Regeneron Pharmaceuticals, Inc., meanwhile, is up 6.93% y... | Among large Healthcare stocks, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) and AbbVie Inc (Symbol: ABBV) are the most notable, showing a loss of 5.0% and 4.7%, respectively. Regeneron Pharmaceuticals, Inc., meanwhile, is up 6.93% year-to-date, and AbbVie Inc, is down 2.02% year-to-date. Combined, REGN and ABBV make ... | Among large Healthcare stocks, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) and AbbVie Inc (Symbol: ABBV) are the most notable, showing a loss of 5.0% and 4.7%, respectively. Regeneron Pharmaceuticals, Inc., meanwhile, is up 6.93% year-to-date, and AbbVie Inc, is down 2.02% year-to-date. Combined, REGN and ABBV make ... | Among large Healthcare stocks, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) and AbbVie Inc (Symbol: ABBV) are the most notable, showing a loss of 5.0% and 4.7%, respectively. Regeneron Pharmaceuticals, Inc., meanwhile, is up 6.93% year-to-date, and AbbVie Inc, is down 2.02% year-to-date. Combined, REGN and ABBV make ... |
24,243 | 2021-01-26 00:00:00 UTC | 2 Stocks I'll Hold Forever | ABBV | https://www.nasdaq.com/articles/2-stocks-ill-hold-forever-2021-01-26 | null | null | Part of the joy of investing is seeing your good investments continue to grow, years after your initial purchase. Aside from the financial satisfaction that you get from seeing a stock's value rise over time, you also get to savor that oh-so-precious feeling: I was right.
Once you've had enough self-congratulation, you... | Where other companies might try to get their drugs approved for one or two other indications after launch, AbbVie never stops investing in its winners, and its shareholders tend to benefit as a result. AbbVie As a major pharma company, AbbVie (NYSE: ABBV) delivers for its investors by developing and commercializing new... | It's this organizational talent for making its products increasingly lucrative over time that makes AbbVie worth holding forever. AbbVie As a major pharma company, AbbVie (NYSE: ABBV) delivers for its investors by developing and commercializing new drugs, like its best-selling arthritis treatment Humira. There's two re... | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Alex Carchidi owns shares of Abbott Laboratories and AbbVie. AbbVie As a major pharma company, AbbVie (NYSE: ABBV) delivers for its ... | AbbVie As a major pharma company, AbbVie (NYSE: ABBV) delivers for its investors by developing and commercializing new drugs, like its best-selling arthritis treatment Humira. There's two reasons AbbVie is worth holding forever: its skill with drug development, and its generous dividend. Like many other pharma companie... |
24,244 | 2021-01-26 00:00:00 UTC | 3 Stocks to Bankroll Your Retirement | ABBV | https://www.nasdaq.com/articles/3-stocks-to-bankroll-your-retirement-2021-01-26 | null | null | When you're choosing the right stocks to help fund your retirement, you need stable, safe income producers -- companies that have steady, if not spectacular growth, with above-average dividend yields. But that doesn't mean you have to buy the same stocks your grandparents did.
Ideally, the stocks you pick are on the cu... | That's why I recommend AbbVie (NYSE: ABBV), PetMed Express (NASDAQ: PETS) and Crown Castle International (NYSE: CCI). AbbVie: An outstanding dividend, plus growth AbbVie is a retiree's dream stock. PETS Payout Ratio data by YCharts AbbVie is also a predictable growth stock with increased revenue every year. | That's why I recommend AbbVie (NYSE: ABBV), PetMed Express (NASDAQ: PETS) and Crown Castle International (NYSE: CCI). AbbVie: An outstanding dividend, plus growth AbbVie is a retiree's dream stock. PETS Payout Ratio data by YCharts AbbVie is also a predictable growth stock with increased revenue every year. | PETS Payout Ratio data by YCharts AbbVie is also a predictable growth stock with increased revenue every year. Of the three, AbbVie is the easiest choice because it has the highest dividend yield, strongest dividend growth history, and greatest track record of revenue growth. That's why I recommend AbbVie (NYSE: ABBV),... | PETS Payout Ratio data by YCharts AbbVie is also a predictable growth stock with increased revenue every year. That's why I recommend AbbVie (NYSE: ABBV), PetMed Express (NASDAQ: PETS) and Crown Castle International (NYSE: CCI). AbbVie: An outstanding dividend, plus growth AbbVie is a retiree's dream stock. |
24,245 | 2021-01-26 00:00:00 UTC | Warren Buffett's 3 Biggest Stock Picks for 2021 | ABBV | https://www.nasdaq.com/articles/warren-buffetts-3-biggest-stock-picks-for-2021-2021-01-26 | null | null | Warren Buffett turned 90 late last year. The stock-picking giant has a loyal following within the investment community. The Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B) CEO still plays an instrumental role in guiding the investment decisions of his conglomerate, albeit with help from investment managers who might eve... | For instance, in the most recent quarter, Berkshire sold about 36 million shares of Apple, helping it take new positions in pharmaceutical stocks like Bristol Myers Squibb (NYSE: BMY), AbbVie (NYSE: ABBV), and Merck (NYSE: MRK). That's actually up from his total investment this time last year, and Buffett's nearly 12% ... | For instance, in the most recent quarter, Berkshire sold about 36 million shares of Apple, helping it take new positions in pharmaceutical stocks like Bristol Myers Squibb (NYSE: BMY), AbbVie (NYSE: ABBV), and Merck (NYSE: MRK). Berkshire still has more than 1 billion shares of the banking giant, worth about $31 billio... | For instance, in the most recent quarter, Berkshire sold about 36 million shares of Apple, helping it take new positions in pharmaceutical stocks like Bristol Myers Squibb (NYSE: BMY), AbbVie (NYSE: ABBV), and Merck (NYSE: MRK). See the 10 stocks *Stock Advisor returns as of November 20, 2020 Dan Caplinger owns shares ... | For instance, in the most recent quarter, Berkshire sold about 36 million shares of Apple, helping it take new positions in pharmaceutical stocks like Bristol Myers Squibb (NYSE: BMY), AbbVie (NYSE: ABBV), and Merck (NYSE: MRK). Berkshire has had the same 400 million share position in Coca-Cola for more than 25 years, ... |
24,246 | 2021-01-25 00:00:00 UTC | 3 Reasons To Invest in Pfizer Stock Despite Its Dismal Performance | ABBV | https://www.nasdaq.com/articles/3-reasons-to-invest-in-pfizer-stock-despite-its-dismal-performance-2021-01-25 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Pfizer (NYSE:PFE) stock is down nearly 1% so far this year. That’s strange, considering it got its vaccine out the door in record time. The novel coronavirus pandemic has wreaked havoc on the global economy. Pfizer and BioNTech’s (NASDAQ:BNTX) vaccine recei... | The only company with a close to 4.3% yield is AbbVie (NYSE:ABBV), with 4.7%. Source: Chart courtesy of StockRover.com Besides, the emergence of a new variant of the disease makes investors rethink the logic of abandoning pharmaceutical stocks quickly. Considering the kind of sales growth the company is expected to see... | The only company with a close to 4.3% yield is AbbVie (NYSE:ABBV), with 4.7%. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pfizer (NYSE:PFE) stock is down nearly 1% so far this year. Pfizer and BioNTech’s (NASDAQ:BNTX) vaccine received Emergency Use Authorization (EUA) due to its excellent efficacy of... | The only company with a close to 4.3% yield is AbbVie (NYSE:ABBV), with 4.7%. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pfizer (NYSE:PFE) stock is down nearly 1% so far this year. Pfizer Stock Is a Value Play in the Pharma Sector Vaccine stocks are slowly losing steam after a bumper 2020. | The only company with a close to 4.3% yield is AbbVie (NYSE:ABBV), with 4.7%. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pfizer (NYSE:PFE) stock is down nearly 1% so far this year. Considering the kind of sales growth the company is expected to see for the next couple of years, there is no danger it... |
24,247 | 2021-01-22 00:00:00 UTC | 7 Dividend Aristocrats That Will Outlive Us All | ABBV | https://www.nasdaq.com/articles/7-dividend-aristocrats-that-will-outlive-us-all-2021-01-22 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Most long-term investors love passive income stocks. Therefore, today we introduce seven “Dividend Aristocrats,” or businesses that have increased the base dividend every year for the past 25 years.
According to metrics from S&P Global (NYSE:SPGI), “Since 1... | With that information, here are seven Dividend Aristocrats that deserve your attention in 2021: 7 Airline Stocks Being Fueled by Vaccine News AbbVie (NYSE:ABBV) Albemarle (NYSE:ALB) Automatic Data Processing (NASDAQ:ADP) Chubb (NYSE:CB) Emerson Electric (NYSE:EMR) ProShares S&P 500 Dividend Aristocrats ETF (BACS:NOBL) ... | With that information, here are seven Dividend Aristocrats that deserve your attention in 2021: 7 Airline Stocks Being Fueled by Vaccine News AbbVie (NYSE:ABBV) Albemarle (NYSE:ALB) Automatic Data Processing (NASDAQ:ADP) Chubb (NYSE:CB) Emerson Electric (NYSE:EMR) ProShares S&P 500 Dividend Aristocrats ETF (BACS:NOBL) ... | With that information, here are seven Dividend Aristocrats that deserve your attention in 2021: 7 Airline Stocks Being Fueled by Vaccine News AbbVie (NYSE:ABBV) Albemarle (NYSE:ALB) Automatic Data Processing (NASDAQ:ADP) Chubb (NYSE:CB) Emerson Electric (NYSE:EMR) ProShares S&P 500 Dividend Aristocrats ETF (BACS:NOBL) ... | With that information, here are seven Dividend Aristocrats that deserve your attention in 2021: 7 Airline Stocks Being Fueled by Vaccine News AbbVie (NYSE:ABBV) Albemarle (NYSE:ALB) Automatic Data Processing (NASDAQ:ADP) Chubb (NYSE:CB) Emerson Electric (NYSE:EMR) ProShares S&P 500 Dividend Aristocrats ETF (BACS:NOBL) ... |
24,248 | 2021-01-17 00:00:00 UTC | The Biggest Drug Competition in 2021 (Hint: It Isn't COVID Vaccines) | ABBV | https://www.nasdaq.com/articles/the-biggest-drug-competition-in-2021-hint%3A-it-isnt-covid-vaccines-2021-01-17 | null | null | In this video from Motley Fool Live, recorded on Jan. 4, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss the upcoming four-way competition for patients with eczema. Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have captured a large share of th... | AbbVie (NYSE: ABBV) has Rinvoq. In this video from Motley Fool Live, recorded on Jan. 4, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss the upcoming four-way competition for patients with eczema. Then Incyte has a cream that's a form of their same active ingredie... | AbbVie (NYSE: ABBV) has Rinvoq. Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have captured a large share of the moderate-to-severe patients with their injected drug Dupixent. But there's still a pretty large market for moderate-to-severe patients. | AbbVie (NYSE: ABBV) has Rinvoq. In this video from Motley Fool Live, recorded on Jan. 4, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss the upcoming four-way competition for patients with eczema. It's been approved for eczema in the EU, and then we should start t... | AbbVie (NYSE: ABBV) has Rinvoq. But it should happen probably in October of next year, assuming they get a standard approval review. They're planning on submitting a marketing application to the FDA. |
24,249 | 2021-01-17 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 1/17/2021 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-1-17-2021-2021-01-17 | null | null | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
DAVITA INC (DVA) is a large-cap growth... | Detailed Analysis of QUEST DIAGNOSTICS INC Full Guru Analysis for DGX> Full Factor Report for DGX> ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analy... | Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV> Full Factor Report for ABBV> HCA HEALTHCARE INC (HCA) is a large-cap growth stock in the Healthcare Facilities industry. Detailed Analysis of QUEST DIAGNOSTICS INC Full Guru Analysis for DGX> Full Factor Report for DGX> ABBVIE INC (ABBV) is a large-cap growth... | Detailed Analysis of QUEST DIAGNOSTICS INC Full Guru Analysis for DGX> Full Factor Report for DGX> ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analy... | Detailed Analysis of QUEST DIAGNOSTICS INC Full Guru Analysis for DGX> Full Factor Report for DGX> ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analy... |
24,250 | 2021-01-15 00:00:00 UTC | Notable ETF Inflow Detected - IWV, TMO, KO, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-iwv-tmo-ko-abbv-2021-01-15 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $125.6 million dollar inflow -- that's a 1.2% increase week over week in outstanding units (from 47,300,000 to 47... | Among the largest underlying components of IWV, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.3%, Coca-Cola Co (Symbol: KO) is down about 1.3%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.6%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one y... | Among the largest underlying components of IWV, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.3%, Coca-Cola Co (Symbol: KO) is down about 1.3%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.6%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one y... | Among the largest underlying components of IWV, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.3%, Coca-Cola Co (Symbol: KO) is down about 1.3%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... | Among the largest underlying components of IWV, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.3%, Coca-Cola Co (Symbol: KO) is down about 1.3%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... |
24,251 | 2021-01-15 00:00:00 UTC | 3 Green Flags for AbbVie in 2021 and 1 Red Flag | ABBV | https://www.nasdaq.com/articles/3-green-flags-for-abbvie-in-2021-and-1-red-flag-2021-01-15 | null | null | If you can identify leading companies in growing industries, you'll be well on your way to finding stocks that will bolster your portfolio's value. Beyond that, it helps to pick companies that have investor-friendly policies -- not to mention favorable tailwinds or upcoming catalysts for growth.
In that vein, after an ... | AbbVie is currently awaiting regulatory review of its evidence that Rinvoq is effective for psoriatic arthritis, atopic dermatitis, and ankylosing spondylitis. continue to grow in the U.S. AbbVie's drug Humira for rheumatoid arthritis is its largest earner, netting the company an estimated $16 billion from its U.S. sal... | Three new Rinvoq indications Rinvoq, one of AbbVie's drugs for rheumatoid arthritis, is already on the market. Skyrizi's phase 3 data update Sometime this year, AbbVie will provide an update from Skyrizi's phase 3 clinical trial for Crohn's disease. In that vein, after an excellent 2020, the pharma company AbbVie (NYSE... | continue to grow in the U.S. AbbVie's drug Humira for rheumatoid arthritis is its largest earner, netting the company an estimated $16 billion from its U.S. sales in 2020 alone. But biosimilars are thrashing Humira revenue in international markets Even though AbbVie is still seeing revenue growth from Humira in the U.S... | continue to grow in the U.S. AbbVie's drug Humira for rheumatoid arthritis is its largest earner, netting the company an estimated $16 billion from its U.S. sales in 2020 alone. In that vein, after an excellent 2020, the pharma company AbbVie (NYSE: ABBV) is positioned for an encore performance in 2021. Three new Rinvo... |
24,252 | 2021-01-14 00:00:00 UTC | 3 Great Dividend Stocks That Are Simply Too Cheap to Ignore | ABBV | https://www.nasdaq.com/articles/3-great-dividend-stocks-that-are-simply-too-cheap-to-ignore-2021-01-14 | null | null | There's a problem with many dividend stocks on the market right now. It's not that their dividends are too low; instead, their valuations are too high. When the next bear market comes, investors who bought the stocks for the great dividends could be stuck with big losses. Those losses could easily more than wipe out al... | AbbVie AbbVie (NYSE: ABBV) ranks as one of the least expensive healthcare stocks on the market. AbbVie's dividend currently yields over 4.7%. AbbVie's record stands at 49 years in a row of dividend hikes. | Bristol Myers Squibb Bristol Myers Squibb (NYSE: BMY) is another big drugmaker that's even cheaper than AbbVie. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Pfizer, and Viatris Inc. AbbVie AbbVie (NYSE: ABBV) ranks as one of the least expen... | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Pfizer, and Viatris Inc. AbbVie AbbVie (NYSE: ABBV) ranks as one of the least expensive healthcare stocks on the market. AbbVie's dividend currently yields over 4.7%. | AbbVie AbbVie (NYSE: ABBV) ranks as one of the least expensive healthcare stocks on the market. AbbVie's dividend currently yields over 4.7%. AbbVie's record stands at 49 years in a row of dividend hikes. |
24,253 | 2021-01-13 00:00:00 UTC | Health Care Sector Update for 01/13/2021: QTRX,MRNS,HSKA,HARP,ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-01-13-2021%3A-qtrxmrnshskaharpabbv-2021-01-13 | null | null | Health care stocks were ending mostly higher this afternoon, with the NYSE Health Care Index rising 0.5% while the SPDR Health Care Select Sector ETF also was ahead 0.4%.
The Nasdaq Biotechnology index was climbing 0.1%.
In company news, Quanterix (QTRX) raced nearly14% higher after the digital biomarker analysis compa... | Harpoon Therapeutics (HARP) has turned 3.1% lower this afternoon, giving back a more than 5% gain earlier Wednesday that followed it saying the US Food and Drug Administration has granted orphan drug designation for its HPN217 drug candidate it is co-developing with AbbVie (ABBV) for the treatment of multiple myeloma. ... | Harpoon Therapeutics (HARP) has turned 3.1% lower this afternoon, giving back a more than 5% gain earlier Wednesday that followed it saying the US Food and Drug Administration has granted orphan drug designation for its HPN217 drug candidate it is co-developing with AbbVie (ABBV) for the treatment of multiple myeloma. ... | Harpoon Therapeutics (HARP) has turned 3.1% lower this afternoon, giving back a more than 5% gain earlier Wednesday that followed it saying the US Food and Drug Administration has granted orphan drug designation for its HPN217 drug candidate it is co-developing with AbbVie (ABBV) for the treatment of multiple myeloma. ... | Harpoon Therapeutics (HARP) has turned 3.1% lower this afternoon, giving back a more than 5% gain earlier Wednesday that followed it saying the US Food and Drug Administration has granted orphan drug designation for its HPN217 drug candidate it is co-developing with AbbVie (ABBV) for the treatment of multiple myeloma. ... |
24,254 | 2021-01-13 00:00:00 UTC | Health Care Sector Update for 01/13/2021: MRNS,HSKA,HARP,ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-01-13-2021%3A-mrnshskaharpabbv-2021-01-13 | null | null | Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 0.4% while the SPDR Health Care Select Sector ETF also was ahead 0.5%.
The Nasdaq Biotechnology index was climbing 0.5%.
In company news, Marinus Pharmaceuticals (MRNS) rose 6% after it received a positive response from the US ... | Harpoon Therapeutics (HARP) has turned 2.5% lower this afternoon, giving back a more than 5% gain earlier Wednesday that followed it saying the US Food and Drug Administration has granted orphan drug designation for its HPN217 drug candidate it is co-developing with AbbVie (ABBV) for the treatment of multiple myeloma. ... | Harpoon Therapeutics (HARP) has turned 2.5% lower this afternoon, giving back a more than 5% gain earlier Wednesday that followed it saying the US Food and Drug Administration has granted orphan drug designation for its HPN217 drug candidate it is co-developing with AbbVie (ABBV) for the treatment of multiple myeloma. ... | Harpoon Therapeutics (HARP) has turned 2.5% lower this afternoon, giving back a more than 5% gain earlier Wednesday that followed it saying the US Food and Drug Administration has granted orphan drug designation for its HPN217 drug candidate it is co-developing with AbbVie (ABBV) for the treatment of multiple myeloma. ... | AbbVie was 2.9% higher this afternoon. Harpoon Therapeutics (HARP) has turned 2.5% lower this afternoon, giving back a more than 5% gain earlier Wednesday that followed it saying the US Food and Drug Administration has granted orphan drug designation for its HPN217 drug candidate it is co-developing with AbbVie (ABBV) ... |
24,255 | 2021-01-13 00:00:00 UTC | AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for January 14, 2021 | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-ex-dividend-date-scheduled-for-january-14-2021-2021-01-13 | null | null | AbbVie Inc. (ABBV) will begin trading ex-dividend on January 14, 2021. A cash dividend payment of $1.3 per share is scheduled to be paid on February 16, 2021. Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 10.17% increase over prior dividend ... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABBV's forecasted earnings growth in 2020 as 17.27%, compared to an industry average of 11.1%. For more information on the declaration, record and payment dates, visit the ABBV Div... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. The following ETF(s) have ABBV as a top-10 holding: VictoryShares US EQ Income Enhanced Volatility Wtd ETF (CDC) VictoryShares US Large Cap High Div Volatility Wtd ETF (CDL) VictoryShares US 500 Volatility Wtd ETF ... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. The following ETF(s) have ABBV as a top-10 holding: VictoryShares US EQ Income Enhanced Volatility Wtd ETF (C... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. AbbVie Inc. (ABBV) will begin trading ex-dividend on January 14, 2021. The previous trading day's last sale of ABBV was $109.78, representing a 0.58% decrease from the 52 week high of $109.15 and a 75.51% increase ... |
24,256 | 2021-01-13 00:00:00 UTC | 3 Dividend Aristocrats to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-aristocrats-to-buy-right-now-2021-01-13 | null | null | There's a lot to like about consistency. That's true for people. And it's true for stocks -- especially dividend stocks. Investors want to be able to count on dividend payments that are like clockwork.
It's even better when that consistency isn't just related to paying dividends but also includes dividend increases. Di... | AbbVie If you like Abbott Labs' dividend, you'll probably love the company's spin-off -- AbbVie (NYSE: ABBV). Because it was part of Abbott until 2013 and has continued to increase its dividend every year, AbbVie's track record of dividend increases mirrors its parent company. But AbbVie's dividend yield of nearly 4.8%... | AbbVie If you like Abbott Labs' dividend, you'll probably love the company's spin-off -- AbbVie (NYSE: ABBV). Because it was part of Abbott until 2013 and has continued to increase its dividend every year, AbbVie's track record of dividend increases mirrors its parent company. But AbbVie's dividend yield of nearly 4.8%... | Because it was part of Abbott until 2013 and has continued to increase its dividend every year, AbbVie's track record of dividend increases mirrors its parent company. AbbVie If you like Abbott Labs' dividend, you'll probably love the company's spin-off -- AbbVie (NYSE: ABBV). But AbbVie's dividend yield of nearly 4.8%... | AbbVie If you like Abbott Labs' dividend, you'll probably love the company's spin-off -- AbbVie (NYSE: ABBV). Because it was part of Abbott until 2013 and has continued to increase its dividend every year, AbbVie's track record of dividend increases mirrors its parent company. But AbbVie's dividend yield of nearly 4.8%... |
24,257 | 2021-01-12 00:00:00 UTC | Ex-Dividend Reminder: DTE Energy, AbbVie and Patterson Companies | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-dte-energy-abbvie-and-patterson-companies-2021-01-12 | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 1/14/21, DTE Energy Co (Symbol: DTP), AbbVie Inc (Symbol: ABBV), and Patterson Companies Inc (Symbol: PDCO) will all trade ex-dividend for their respective upcoming dividends. DTE Energy Co will pay its quarterly dividend of $0.7812 on 2/1/21, AbbVie In... | If they do continue, the current estimated yields on annualized basis would be 6.65% for DTE Energy Co, 4.73% for AbbVie Inc, and 3.24% for Patterson Companies Inc. Looking at the universe of stocks we cover at Dividend Channel, on 1/14/21, DTE Energy Co (Symbol: DTP), AbbVie Inc (Symbol: ABBV), and Patterson Companies... | Looking at the universe of stocks we cover at Dividend Channel, on 1/14/21, DTE Energy Co (Symbol: DTP), AbbVie Inc (Symbol: ABBV), and Patterson Companies Inc (Symbol: PDCO) will all trade ex-dividend for their respective upcoming dividends. DTE Energy Co will pay its quarterly dividend of $0.7812 on 2/1/21, AbbVie In... | Looking at the universe of stocks we cover at Dividend Channel, on 1/14/21, DTE Energy Co (Symbol: DTP), AbbVie Inc (Symbol: ABBV), and Patterson Companies Inc (Symbol: PDCO) will all trade ex-dividend for their respective upcoming dividends. DTE Energy Co will pay its quarterly dividend of $0.7812 on 2/1/21, AbbVie In... | Looking at the universe of stocks we cover at Dividend Channel, on 1/14/21, DTE Energy Co (Symbol: DTP), AbbVie Inc (Symbol: ABBV), and Patterson Companies Inc (Symbol: PDCO) will all trade ex-dividend for their respective upcoming dividends. If they do continue, the current estimated yields on annualized basis would b... |
24,258 | 2021-01-12 00:00:00 UTC | How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside | ABBV | https://www.nasdaq.com/articles/how-to-play-stock-spinoffs-for-176-payout-growth-200-upside-2021-01-12 | null | null | Let's start 2021 with a proven strategy for grabbing two growing income streams in one buy. Plus, we'll nicely set ourselves up to bank double-digit price gains to boot.
The strategy? Simple: we're buying dividend-paying stocks poised to spin off one of their businesses into a brand-new dividend-paying stock. When that... | And make no mistake, growing dividends are critical to our strategy--as AbbVie and Abbott showed, you can set yourself up for outperformance if you grab shares of upcoming or recent spinoffs with a history of hiking their payouts. How Spinoffs Can Deliver Triple-Digit Gains, Accelerating Payouts Medical-equipment maker... | And if Abbott investors held on to their AbbVie shares, their holdings skyrocketed as other income-seekers noticed these rapid payout hikes and bought in, driving up the prices of both companies in lockstep with their rising payouts: ... Driving Fast Price Gains, Too! How Spinoffs Can Deliver Triple-Digit Gains, Accele... | How Spinoffs Can Deliver Triple-Digit Gains, Accelerating Payouts Medical-equipment maker Abbott Labs (ABT) and its spinoff, pharmaceutical firm AbbVie (ABBV), are classic examples of the gains (and fast-growing dividends) a spinoff can hand us. Abbott, for its part, had reduced its payout to $0.14 a share to account f... | On the day of the split, Abbott investors were handed one share of AbbVie for every Abbott share they owned, and the new firm set its payout at $0.40 a share quarterly. How Spinoffs Can Deliver Triple-Digit Gains, Accelerating Payouts Medical-equipment maker Abbott Labs (ABT) and its spinoff, pharmaceutical firm AbbVie... |
24,259 | 2021-01-11 00:00:00 UTC | Noteworthy Monday Option Activity: ABBV, DVA, LUV | ABBV | https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-abbv-dva-luv-2021-01-11 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 34,338 contracts have traded so far, representing approximately 3.4 million underlying shares. That amounts to about 49.6% of ABBV's average daily trading volume over the p... | Particularly high volume was seen for the $120 strike call option expiring February 19, 2021, with 3,729 contracts trading so far today, representing approximately 372,900 underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbo... | Below is a chart showing ABBV's trailing twelve month trading history, with the $120 strike highlighted in orange: DaVita Inc (Symbol: DVA) saw options trading volume of 3,208 contracts, representing approximately 320,800 underlying shares or approximately 46.1% of DVA's average daily trading volume over the past month... | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 34,338 contracts have traded so far, representing approximately 3.4 million underlying shares. Below is a chart showing ABBV's trailing twelve month trading history, with t... | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 34,338 contracts have traded so far, representing approximately 3.4 million underlying shares. That amounts to about 49.6% of ABBV's average daily trading volume over the p... |
24,260 | 2021-01-11 00:00:00 UTC | 7 Hot Stocks That Will Keep You Energized With 3%-Plus Yields | ABBV | https://www.nasdaq.com/articles/7-hot-stocks-that-will-keep-you-energized-with-3-plus-yields-2021-01-11 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In a market like this, most people aren’t hunting for income stocks. Instead, they’re looking for hot stocks with turbocharged growth potential.
Now, that’s fine for part of your portfolio. But a well-balanced portfolio also needs stocks that are able to wi... | Abbvie (NYSE:ABBV) Broadcom (NASDAQ:AVGO) Coresite Realty (NYSE:COR) Flowers Foods (NYSE:FLO) General Mills (NYSE:GIS) NextEra Energy Partners (NYSE:NEP) J.M. Smucker (NYSE:SJM) Abbvie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com Humira is one of the wor... | Abbvie (NYSE:ABBV) Broadcom (NASDAQ:AVGO) Coresite Realty (NYSE:COR) Flowers Foods (NYSE:FLO) General Mills (NYSE:GIS) NextEra Energy Partners (NYSE:NEP) J.M. Smucker (NYSE:SJM) Abbvie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com Humira is one of the wor... | Abbvie (NYSE:ABBV) Broadcom (NASDAQ:AVGO) Coresite Realty (NYSE:COR) Flowers Foods (NYSE:FLO) General Mills (NYSE:GIS) NextEra Energy Partners (NYSE:NEP) J.M. Smucker (NYSE:SJM) Abbvie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com Humira is one of the wor... | Abbvie (NYSE:ABBV) Broadcom (NASDAQ:AVGO) Coresite Realty (NYSE:COR) Flowers Foods (NYSE:FLO) General Mills (NYSE:GIS) NextEra Energy Partners (NYSE:NEP) J.M. Smucker (NYSE:SJM) Abbvie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com Humira is one of the wor... |
24,261 | 2021-01-11 00:00:00 UTC | The Top 7 Pharmaceutical Stocks for the Next 10 Years | ABBV | https://www.nasdaq.com/articles/the-top-7-pharmaceutical-stocks-for-the-next-10-years-2021-01-11 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Each industry within the stock market has its own unique set of factors that determine the success of stocks in that niche. Pharmaceutical stocks are no exception. Investors looking to take positions in pharmaceutical shares need to consider the unique fact... | Let’s take a look: Pfizer (NYSE:PFE) Bristol-Myers Squibb (NYSE:BMY) AbbVie (NYSE:ABBV) Sanofi (NYSE:SNY) Takeda (NYSE:TAK) Novartis (NYSE:NVS) Johnson & Johnson (NYSE:JNJ) Pharmaceutical Stocks: Pfizer (PFE) PFE) logo on Pfizer building. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">So... | Let’s take a look: Pfizer (NYSE:PFE) Bristol-Myers Squibb (NYSE:BMY) AbbVie (NYSE:ABBV) Sanofi (NYSE:SNY) Takeda (NYSE:TAK) Novartis (NYSE:NVS) Johnson & Johnson (NYSE:JNJ) Pharmaceutical Stocks: Pfizer (PFE) PFE) logo on Pfizer building. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">So... | Let’s take a look: Pfizer (NYSE:PFE) Bristol-Myers Squibb (NYSE:BMY) AbbVie (NYSE:ABBV) Sanofi (NYSE:SNY) Takeda (NYSE:TAK) Novartis (NYSE:NVS) Johnson & Johnson (NYSE:JNJ) Pharmaceutical Stocks: Pfizer (PFE) PFE) logo on Pfizer building. AbbVie’s CEO believes that the company’s pipeline of drugs will more than shore u... | Let’s take a look: Pfizer (NYSE:PFE) Bristol-Myers Squibb (NYSE:BMY) AbbVie (NYSE:ABBV) Sanofi (NYSE:SNY) Takeda (NYSE:TAK) Novartis (NYSE:NVS) Johnson & Johnson (NYSE:JNJ) Pharmaceutical Stocks: Pfizer (PFE) PFE) logo on Pfizer building. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169">So... |
24,262 | 2021-01-10 00:00:00 UTC | 3 Reasons to Invest in Dividend-Paying Stocks for Retirement | ABBV | https://www.nasdaq.com/articles/3-reasons-to-invest-in-dividend-paying-stocks-for-retirement-2021-01-10 | null | null | Today's workers face plenty of challenges when preparing for retirement. Costs are rising, and life expectancy is increasing, meaning you'll need to save more than ever. At the same time, though, many workers don't have access to pensions, and Social Security benefits are at risk of cuts in the relatively near future.
... | By comparison, stocks like ExxonMobil and Abbvie -- both Dividend Aristocrats -- have dividend yields of more than 4% as of this writing. At the same time, though, many workers don't have access to pensions, and Social Security benefits are at risk of cuts in the relatively near future. When companies have leftover ear... | By comparison, stocks like ExxonMobil and Abbvie -- both Dividend Aristocrats -- have dividend yields of more than 4% as of this writing. They can boost your retirement income Dividend stocks are unique in that they actually pay you to own them. Many dividend stocks increase their dividends year after year. | By comparison, stocks like ExxonMobil and Abbvie -- both Dividend Aristocrats -- have dividend yields of more than 4% as of this writing. By investing in dividend stocks that reliably increase their dividend payments each year, you can limit the effect inflation has on your savings. Investing in dividend stocks is a go... | By comparison, stocks like ExxonMobil and Abbvie -- both Dividend Aristocrats -- have dividend yields of more than 4% as of this writing. Many dividend stocks increase their dividends year after year. Investing in dividend stocks is a good compromise between putting your money in a savings account and investing in the ... |
24,263 | 2021-01-09 00:00:00 UTC | How Safe Is AbbVie's Dividend? | ABBV | https://www.nasdaq.com/articles/how-safe-is-abbvies-dividend-2021-01-09 | null | null | It's human nature to worry. There's a reason why old adages such as "all good things must come to an end" remain widely used -- we tend to expect something to go wrong.
For income-seeking investors, everything has gone right with AbbVie (NYSE: ABBV) for a long time. The big drugmaker's dividends have steadily increased... | As already discussed, AbbVie is in a much stronger position to maintain its dividend, at least at current levels, than a cursory glance at its payout ratio and Humira prospects reflect. For income-seeking investors, everything has gone right with AbbVie (NYSE: ABBV) for a long time. Just how safe is AbbVie's dividend? | Then there's AbbVie's dividend payout ratio -- the percentage of earnings paid out as dividends. For income-seeking investors, everything has gone right with AbbVie (NYSE: ABBV) for a long time. Just how safe is AbbVie's dividend? | Then there's AbbVie's dividend payout ratio -- the percentage of earnings paid out as dividends. Marked safe Just as people mark themselves as safe on social media during catastrophic events, I think we can mark AbbVie's dividend as safe, despite the coming challenges for Humira. AbbVie's track record of 49 years in a ... | My view is that AbbVie will keep the dividends flowing and growing for a long time to come. For income-seeking investors, everything has gone right with AbbVie (NYSE: ABBV) for a long time. Just how safe is AbbVie's dividend? |
24,264 | 2021-01-09 00:00:00 UTC | 3 Stocks That Are Absurdly Cheap Right Now | ABBV | https://www.nasdaq.com/articles/3-stocks-that-are-absurdly-cheap-right-now-2021-01-09 | null | null | One of the best ways to maximize your odds of earning a great return on a stock is to buy it when it's dirt cheap. But with the average stock on the S&P 500 now trading at more than 27 times its earnings and the index soaring 15% over the past 12 months, it's not easy for investors to find great deals.
The good news is... | Three ridiculously cheap stocks that you should consider buying right now are AbbVie (NYSE: ABBV), Lumen Technologies (NYSE: LUMN), and Dell (NYSE: DELL). AbbVie AbbVie is a top healthcare stock that got a whole lot bigger in 2019 after closing on its $63 billion deal to acquire Botox-maker Allergan. Although the immun... | Three ridiculously cheap stocks that you should consider buying right now are AbbVie (NYSE: ABBV), Lumen Technologies (NYSE: LUMN), and Dell (NYSE: DELL). Through the nine-month period ending Sept. 30, AbbVie's total revenue of $31.9 billion was up 30% from the prior-year period -- largely due to the inclusion of Aller... | Three ridiculously cheap stocks that you should consider buying right now are AbbVie (NYSE: ABBV), Lumen Technologies (NYSE: LUMN), and Dell (NYSE: DELL). AbbVie AbbVie is a top healthcare stock that got a whole lot bigger in 2019 after closing on its $63 billion deal to acquire Botox-maker Allergan. Although the immun... | Three ridiculously cheap stocks that you should consider buying right now are AbbVie (NYSE: ABBV), Lumen Technologies (NYSE: LUMN), and Dell (NYSE: DELL). AbbVie AbbVie is a top healthcare stock that got a whole lot bigger in 2019 after closing on its $63 billion deal to acquire Botox-maker Allergan. Although the immun... |
24,265 | 2021-01-09 00:00:00 UTC | AbbVie Inc. (NYSE:ABBV) Will Pay A US$1.30 Dividend In Four Days | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-nyse%3Aabbv-will-pay-a-us%241.30-dividend-in-four-days-2021-01-09 | null | null | It looks like AbbVie Inc. (NYSE:ABBV) is about to go ex-dividend in the next 4 days. You will need to purchase shares before the 14th of January to receive the dividend, which will be paid on the 16th of February.
AbbVie's next dividend payment will be US$1.30 per share. Last year, in total, the company distributed US$... | Last year's total dividend payments show that AbbVie has a trailing yield of 4.8% on the current share price of $107.27. Last year, AbbVie paid out 103% of its income as dividends, which is above a level that we're comfortable with, especially if the company needs to reinvest in its business. It's good to see earnings ... | Last year's total dividend payments show that AbbVie has a trailing yield of 4.8% on the current share price of $107.27. NYSE:ABBV Historic Dividend January 9th 2021 Have Earnings And Dividends Been Growing? It looks like AbbVie Inc. (NYSE:ABBV) is about to go ex-dividend in the next 4 days. | It looks like AbbVie Inc. (NYSE:ABBV) is about to go ex-dividend in the next 4 days. AbbVie's next dividend payment will be US$1.30 per share. Last year's total dividend payments show that AbbVie has a trailing yield of 4.8% on the current share price of $107.27. | It's good to see earnings per share growing and low cashflow payout ratio, although we're uncomfortable with AbbVie's paying out such a high percentage of its profit. It looks like AbbVie Inc. (NYSE:ABBV) is about to go ex-dividend in the next 4 days. AbbVie's next dividend payment will be US$1.30 per share. |
24,266 | 2021-01-07 00:00:00 UTC | AbbVie : Skyrizi Shows Improvements In Clinical Responses In Two Phase 3 Studies On Crohn's Disease | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-skyrizi-shows-improvements-in-clinical-responses-in-two-phase-3-studies-on-crohns | null | null | (RTTNews) - AbbVie (ABBV) said Risankizumab or Skyrizi has demonstrated significant improvements in clinical remission and endoscopic response in two phase 3 induction studies in patients with crohn's disease.
The company noted hat a significantly greater proportion of patients with Crohn's disease treated with either ... | (RTTNews) - AbbVie (ABBV) said Risankizumab or Skyrizi has demonstrated significant improvements in clinical remission and endoscopic response in two phase 3 induction studies in patients with crohn's disease. Risankizumab (Skyrizi) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading... | (RTTNews) - AbbVie (ABBV) said Risankizumab or Skyrizi has demonstrated significant improvements in clinical remission and endoscopic response in two phase 3 induction studies in patients with crohn's disease. Risankizumab (Skyrizi) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading... | (RTTNews) - AbbVie (ABBV) said Risankizumab or Skyrizi has demonstrated significant improvements in clinical remission and endoscopic response in two phase 3 induction studies in patients with crohn's disease. Risankizumab (Skyrizi) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading... | (RTTNews) - AbbVie (ABBV) said Risankizumab or Skyrizi has demonstrated significant improvements in clinical remission and endoscopic response in two phase 3 induction studies in patients with crohn's disease. Risankizumab (Skyrizi) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading... |
24,267 | 2021-01-07 00:00:00 UTC | Adamas Pharma - Starting The Year Off Right? | ABBV | https://www.nasdaq.com/articles/adamas-pharma-starting-the-year-off-right-2021-01-07 | null | null | (RTTNews) - Shares of Adamas Pharmaceuticals Inc. (ADMS) have recovered 140% from their 52-week low of $1.90 recorded on Mar.18, 2020, and trade around $4.50.
Adamas is a commercial-stage pharmaceutical company with a growing portfolio of therapies for neurological diseases. The company's flagship product is GOCOVRI, a... | This drug is marketed in the United States by Allergan plc, now part of AbbVie (ABBV). Adamas has proposed a revision to the indication statement to include GOCOVRI as an appropriate therapy for the treatment of OFF episodes in Parkinson's disease patients receiving levodopa and the FDA decision is expected on February... | This drug is marketed in the United States by Allergan plc, now part of AbbVie (ABBV). The company's flagship product is GOCOVRI, a FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medicines. Adamas bega... | This drug is marketed in the United States by Allergan plc, now part of AbbVie (ABBV). The drug raked in sales of $568 thousand in 2017; $34.05 million in 2018; $54.64 million in 2019; and $51.5 million in the nine months ended Sep.30, 2020. Adamas has proposed a revision to the indication statement to include GOCOVRI ... | This drug is marketed in the United States by Allergan plc, now part of AbbVie (ABBV). Q3, 2020 Highlights The company's total revenue for the third quarter of 2020 was $20.2 million, including GOCOVRI product sales of $19 million and Namzaric royalty revenue of $1.2 million. This compares with total revenue of $13.9 m... |
24,268 | 2021-01-07 00:00:00 UTC | Notable ETF Outflow Detected - IVW, TMO, ABBV, ABT | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-ivw-tmo-abbv-abt-2021-01-07 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $191.2 million dollar outflow -- that's a 0.6% decrease week over week (from 506,500,000 to 503,450,000). Among... | Among the largest underlying components of IVW, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 3.2%, AbbVie Inc (Symbol: ABBV) is up about 1.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.3%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows th... | Among the largest underlying components of IVW, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 3.2%, AbbVie Inc (Symbol: ABBV) is up about 1.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.3%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows th... | Among the largest underlying components of IVW, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 3.2%, AbbVie Inc (Symbol: ABBV) is up about 1.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs c... | Among the largest underlying components of IVW, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 3.2%, AbbVie Inc (Symbol: ABBV) is up about 1.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs c... |
24,269 | 2021-01-06 00:00:00 UTC | MRKR Soars As FDA Lifts Hold On MT-401, RYTM Sells Priority Review Voucher, MLND Dumps MLE-301 | ABBV | https://www.nasdaq.com/articles/mrkr-soars-as-fda-lifts-hold-on-mt-401-rytm-sells-priority-review-voucher-mlnd-dumps-mle | null | null | (RTTNews) - Today's Daily Dose brings you news about the FDA lifting the partial clinical hold on Marker Therapeutics' phase II post-transplant acute myeloid leukemia trial; Rhythm selling its Rare Pediatric Disease Priority Review Voucher for $100 million; Hoth Therapeutics' financing agreement; Millendo discontinuing... | AbbVie Hands Over Rights of muscarinic agonist program to Sosei Sosei Group Corp. (SOLTF.OB) has regained the worldwide rights to its muscarinic agonist programs in development for the treatment of major neurological disorders, including Alzheimer's disease from AbbVie (ABBV). Allergan was acquired by AbbVie in May 202... | AbbVie Hands Over Rights of muscarinic agonist program to Sosei Sosei Group Corp. (SOLTF.OB) has regained the worldwide rights to its muscarinic agonist programs in development for the treatment of major neurological disorders, including Alzheimer's disease from AbbVie (ABBV). Allergan was acquired by AbbVie in May 202... | AbbVie Hands Over Rights of muscarinic agonist program to Sosei Sosei Group Corp. (SOLTF.OB) has regained the worldwide rights to its muscarinic agonist programs in development for the treatment of major neurological disorders, including Alzheimer's disease from AbbVie (ABBV). Allergan was acquired by AbbVie in May 202... | The decision of AbbVie to hand over the worldwide rights to muscarinic agonist programs was based on its pipeline strategy and is not as a result of safety or efficacy data. AbbVie Hands Over Rights of muscarinic agonist program to Sosei Sosei Group Corp. (SOLTF.OB) has regained the worldwide rights to its muscarinic a... |
24,270 | 2021-01-05 00:00:00 UTC | AbbVie Announces Positive Results From Phase 3 Studies In Adults With Active Psoriatic Arthritis | ABBV | https://www.nasdaq.com/articles/abbvie-announces-positive-results-from-phase-3-studies-in-adults-with-active-psoriatic | null | null | (RTTNews) - AbbVie (ABBV) said that two phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 and KEEPsAKE-2, demonstrated that significantly more patients treated with risankizumab (150 mg) achieved the primary endpoint of ACR20 response at week 24 versus placebo.
In KEEPsAKE-1 and KEEPsAKE-2, 57 and 5... | (RTTNews) - AbbVie (ABBV) said that two phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 and KEEPsAKE-2, demonstrated that significantly more patients treated with risankizumab (150 mg) achieved the primary endpoint of ACR20 response at week 24 versus placebo. The company noted that the secondary e... | (RTTNews) - AbbVie (ABBV) said that two phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 and KEEPsAKE-2, demonstrated that significantly more patients treated with risankizumab (150 mg) achieved the primary endpoint of ACR20 response at week 24 versus placebo. In KEEPsAKE-1 and KEEPsAKE-2, 57 and 5... | (RTTNews) - AbbVie (ABBV) said that two phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 and KEEPsAKE-2, demonstrated that significantly more patients treated with risankizumab (150 mg) achieved the primary endpoint of ACR20 response at week 24 versus placebo. In KEEPsAKE-1 and KEEPsAKE-2, 57 and 5... | (RTTNews) - AbbVie (ABBV) said that two phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 and KEEPsAKE-2, demonstrated that significantly more patients treated with risankizumab (150 mg) achieved the primary endpoint of ACR20 response at week 24 versus placebo. In KEEPsAKE-1 and KEEPsAKE-2, 57 and 5... |
24,271 | 2021-01-05 00:00:00 UTC | Got $1,000? These 2 Top Stocks Can Make You Rich | ABBV | https://www.nasdaq.com/articles/got-%241000-these-2-top-stocks-can-make-you-rich-2021-01-05 | null | null | This year the stock market has been on nothing short of a roller coaster ride. The S&P 500 has seen dramatic lows and dizzying highs. On March 23, the index recorded its fastest-ever 30% drop in just 22 trading days. Then, on Dec. 31, it reached a record high of 3,760.
In such unpredictable times, investors find it dif... | AbbVie AbbVie (NYSE: ABBV) offers a solid combination of robust growth prospects and steady income. AbbVie's revenue growth trajectory is closely linked with sales of Humira. This immunosuppressant drug has clocked revenue of $14.7 billion so far this year, almost half of AbbVie's $31.9 billion total revenue. | AbbVie AbbVie (NYSE: ABBV) offers a solid combination of robust growth prospects and steady income. This immunosuppressant drug has clocked revenue of $14.7 billion so far this year, almost half of AbbVie's $31.9 billion total revenue. Hence, despite the Humira U.S. LOE risk, AbbVie offers a favorable risk-reward propo... | This immunosuppressant drug has clocked revenue of $14.7 billion so far this year, almost half of AbbVie's $31.9 billion total revenue. With operating cash flow over $16 billion in last 12 months and a cash balance of $8 billion at the end of the third quarter, AbbVie is definitely in a position to sustain its dividend... | This immunosuppressant drug has clocked revenue of $14.7 billion so far this year, almost half of AbbVie's $31.9 billion total revenue. AbbVie AbbVie (NYSE: ABBV) offers a solid combination of robust growth prospects and steady income. AbbVie's revenue growth trajectory is closely linked with sales of Humira. |
24,272 | 2021-01-04 00:00:00 UTC | Drugmakers kick off 2021 with 500 U.S. price hikes | ABBV | https://www.nasdaq.com/articles/drugmakers-kick-off-2021-with-500-u.s.-price-hikes-2021-01-04 | null | null | By Michael Erman
NEW YORK, Jan 4 (Reuters) - Drugmakers including Abbvie Inc ABBV.N and Bristol Myers Squibb BMY.N raised U.S. list prices on more than 500 drugs to kick off 2021, according to an analysis by health care research firm 46brooklyn.
The hikes come as drugmakers are reeling from effects of the COVID-19 pand... | By Michael Erman NEW YORK, Jan 4 (Reuters) - Drugmakers including Abbvie Inc ABBV.N and Bristol Myers Squibb BMY.N raised U.S. list prices on more than 500 drugs to kick off 2021, according to an analysis by health care research firm 46brooklyn. Abbvie raised prices on around 40 drugs including a 7.4% hike on rheumatoi... | By Michael Erman NEW YORK, Jan 4 (Reuters) - Drugmakers including Abbvie Inc ABBV.N and Bristol Myers Squibb BMY.N raised U.S. list prices on more than 500 drugs to kick off 2021, according to an analysis by health care research firm 46brooklyn. Abbvie raised prices on around 40 drugs including a 7.4% hike on rheumatoi... | Abbvie raised prices on around 40 drugs including a 7.4% hike on rheumatoid arthritis treatment Humira, the world's top-selling drug. By Michael Erman NEW YORK, Jan 4 (Reuters) - Drugmakers including Abbvie Inc ABBV.N and Bristol Myers Squibb BMY.N raised U.S. list prices on more than 500 drugs to kick off 2021, accord... | By Michael Erman NEW YORK, Jan 4 (Reuters) - Drugmakers including Abbvie Inc ABBV.N and Bristol Myers Squibb BMY.N raised U.S. list prices on more than 500 drugs to kick off 2021, according to an analysis by health care research firm 46brooklyn. Abbvie raised prices on around 40 drugs including a 7.4% hike on rheumatoi... |
24,273 | 2021-01-04 00:00:00 UTC | 7 Cheap Stocks to Buy in January For a Quick Buck | ABBV | https://www.nasdaq.com/articles/7-cheap-stocks-to-buy-in-january-for-a-quick-buck-2021-01-04 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
There are always deals to be had in the wake of the holiday season. For one, retailers often look to offload excess inventory after Christmas. But there are also always cheap stocks to buy in January. Now, following such an unprecedented year, the stock mar... | Bristol-Myers Squibb (NYSE:BMY) Intel (NASDAQ:INTC) Southwest Airlines (NYSE:LUV) Aptiv (NYSE:APTV) AbbVie (NYSE:ABBV) Howard Hughes (NYSE:HHC) Disney (NYSE:DIS) Cheap Stocks to Buy: Bristol-Myers Squibb (BMY) BMY) logo displayed on a phone screen" width="300" height="169"> Source: IgorGolovniov / Shutterstock.com Phar... | Bristol-Myers Squibb (NYSE:BMY) Intel (NASDAQ:INTC) Southwest Airlines (NYSE:LUV) Aptiv (NYSE:APTV) AbbVie (NYSE:ABBV) Howard Hughes (NYSE:HHC) Disney (NYSE:DIS) Cheap Stocks to Buy: Bristol-Myers Squibb (BMY) BMY) logo displayed on a phone screen" width="300" height="169"> Source: IgorGolovniov / Shutterstock.com Phar... | Bristol-Myers Squibb (NYSE:BMY) Intel (NASDAQ:INTC) Southwest Airlines (NYSE:LUV) Aptiv (NYSE:APTV) AbbVie (NYSE:ABBV) Howard Hughes (NYSE:HHC) Disney (NYSE:DIS) Cheap Stocks to Buy: Bristol-Myers Squibb (BMY) BMY) logo displayed on a phone screen" width="300" height="169"> Source: IgorGolovniov / Shutterstock.com Phar... | Bristol-Myers Squibb (NYSE:BMY) Intel (NASDAQ:INTC) Southwest Airlines (NYSE:LUV) Aptiv (NYSE:APTV) AbbVie (NYSE:ABBV) Howard Hughes (NYSE:HHC) Disney (NYSE:DIS) Cheap Stocks to Buy: Bristol-Myers Squibb (BMY) BMY) logo displayed on a phone screen" width="300" height="169"> Source: IgorGolovniov / Shutterstock.com Phar... |
24,274 | 2021-01-04 00:00:00 UTC | 3 Top Biotech Buyout Candidates in 2021 | ABBV | https://www.nasdaq.com/articles/3-top-biotech-buyout-candidates-in-2021-2021-01-04 | null | null | Many predictions for the new year probably won't pan out. However, here's one that seems to be a pretty safe bet: There will be several biotech acquisitions. Granted, this prediction is safe because there are several biotech deals made every year.
It's not nearly as easy to accurately forecast which companies will be i... | Sure, AbbVie walked away from a partnership that Allergan had made with Editas to develop gene-editing therapy EDIT-101 for treating genetic eye disorder Leber congenital amaurosis type 10. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Edita... | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Editas Medicine, and Pfizer. Sure, AbbVie walked away from a partnership that Allergan had made with Editas to develop gene-editing therapy EDIT-101 for treating genetic eye disorder Leber congen... | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Editas Medicine, and Pfizer. Sure, AbbVie walked away from a partnership that Allergan had made with Editas to develop gene-editing therapy EDIT-101 for treating genetic eye disorder Leber congen... | Sure, AbbVie walked away from a partnership that Allergan had made with Editas to develop gene-editing therapy EDIT-101 for treating genetic eye disorder Leber congenital amaurosis type 10. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Edita... |
24,275 | 2021-01-01 00:00:00 UTC | These 4 Micro-Cap Healthcare Stocks Gained the Most in 2020 | ABBV | https://www.nasdaq.com/articles/these-4-micro-cap-healthcare-stocks-gained-the-most-in-2020-2021-01-01 | null | null | If you're like me, you're an eternal optimist when it comes to the march of scientific progress and its ability to improve human life. Making new technologies, foods, and medicines is never easy, but it still pays off time and time again for investors and members of the public alike. If you want to get rich off of adva... | While the AbbVie deal is a big break in the short term, Alpine's long-term growth potential rests in its internally developed projects. Alpine Immune Sciences Alpine Immune Sciences (NASDAQ: ALPN) tripled in value this year with a new collaboration worth up to $805 million with AbbVie to develop its ALPN-101 anti-infla... | Alpine Immune Sciences Alpine Immune Sciences (NASDAQ: ALPN) tripled in value this year with a new collaboration worth up to $805 million with AbbVie to develop its ALPN-101 anti-inflammatory drug. While the AbbVie deal is a big break in the short term, Alpine's long-term growth potential rests in its internally develo... | Alpine Immune Sciences Alpine Immune Sciences (NASDAQ: ALPN) tripled in value this year with a new collaboration worth up to $805 million with AbbVie to develop its ALPN-101 anti-inflammatory drug. While the AbbVie deal is a big break in the short term, Alpine's long-term growth potential rests in its internally develo... | Alpine Immune Sciences Alpine Immune Sciences (NASDAQ: ALPN) tripled in value this year with a new collaboration worth up to $805 million with AbbVie to develop its ALPN-101 anti-inflammatory drug. While the AbbVie deal is a big break in the short term, Alpine's long-term growth potential rests in its internally develo... |
24,276 | 2020-12-31 00:00:00 UTC | 3 Stocks That Can Pay You More Than Social Security Benefits | ABBV | https://www.nasdaq.com/articles/3-stocks-that-can-pay-you-more-than-social-security-benefits-2020-12-31 | null | null | Social Security benefits are a major source of income for millions of retirees. In fact, nearly nine in 10 Americans say their benefits will make up at least a portion of their income in retirement, according to a poll from Gallup.
However, the average retiree only receives around $1,500 per month from Social Security,... | AbbVie Healthcare company AbbVie (NYSE: ABBV) is another member of the Dividend Aristocrats, and it has increased its dividend by 195% since 2013. In fact, nearly nine in 10 Americans say their benefits will make up at least a portion of their income in retirement, according to a poll from Gallup. This company currentl... | AbbVie Healthcare company AbbVie (NYSE: ABBV) is another member of the Dividend Aristocrats, and it has increased its dividend by 195% since 2013. How to earn passive income from stocks Not all stocks provide passive income in retirement; the ones that do are called dividend stocks. Chevron Chevron (NYSE: CVX) is part ... | AbbVie Healthcare company AbbVie (NYSE: ABBV) is another member of the Dividend Aristocrats, and it has increased its dividend by 195% since 2013. How to earn passive income from stocks Not all stocks provide passive income in retirement; the ones that do are called dividend stocks. The Dividend Aristocrats are an elit... | AbbVie Healthcare company AbbVie (NYSE: ABBV) is another member of the Dividend Aristocrats, and it has increased its dividend by 195% since 2013. And if you invest enough money in the right stocks, these investments could pay you even more than Social Security benefits. It currently pays $5.20 per year in total quarte... |
24,277 | 2020-12-31 00:00:00 UTC | 3 Warren Buffett Stocks Worth Buying Now | ABBV | https://www.nasdaq.com/articles/3-warren-buffett-stocks-worth-buying-now-2020-12-31 | null | null | When it comes to stock market trading, few investors are more legendary than Warren Buffett. The Oracle of Omaha is one of the richest individuals alive and has amassed a net worth of nearly $90 billion at the time of this writing. Through Buffett's holding company Berkshire Hathaway, the investment mogul controls a su... | AbbVie Shares of large-cap biopharmaceutical company AbbVie (NYSE: ABBV) have risen about 18% over the trailing-12-month period despite extreme fluctuations in the broader market. AbbVie's dividend yield (5.04% based on current share prices) is also well above that of the average stock on the S&P 500, which makes the c... | Because of this, AbbVie reported double-digit year-over-year net revenue growth in each of the first three quarters of 2020: 10.1%, 26.3%, and 52.1%, respectively. AbbVie Shares of large-cap biopharmaceutical company AbbVie (NYSE: ABBV) have risen about 18% over the trailing-12-month period despite extreme fluctuations... | AbbVie Shares of large-cap biopharmaceutical company AbbVie (NYSE: ABBV) have risen about 18% over the trailing-12-month period despite extreme fluctuations in the broader market. AbbVie's dividend yield (5.04% based on current share prices) is also well above that of the average stock on the S&P 500, which makes the c... | Analysts are also expecting great things from AbbVie over the next few years, and project that the company will report double-digit earnings growth every year over the next five years alone. AbbVie Shares of large-cap biopharmaceutical company AbbVie (NYSE: ABBV) have risen about 18% over the trailing-12-month period d... |
24,278 | 2020-12-31 00:00:00 UTC | How to Find the Best Dividend Stocks | ABBV | https://www.nasdaq.com/articles/how-to-find-the-best-dividend-stocks-2020-12-31 | null | null | Dividend-paying stocks can make your financial life much better in a variety of ways. They can provide regular, dependable income year in and year out, no matter what the economy is doing. They can help support you in retirement with that income -- often without your having to sell the dividend-generating shares. Those... | AbbVie 5% 18.3% See the 10 stocks Stock Advisor returns as of 2/1/20 Selena Maranjian owns shares of AbbVie, Apple, AT&T, Realty Income, Starbucks, and Walt Disney. So, for example, if Starbucks (NASDAQ: SBUX) is paying $1.80 per year (in quarterly payments of $0.45) and it's trading at $104 per share, you'd divide $1.... | AbbVie 5% 18.3% See the 10 stocks Stock Advisor returns as of 2/1/20 Selena Maranjian owns shares of AbbVie, Apple, AT&T, Realty Income, Starbucks, and Walt Disney. 7.25% 2% Realty Income 4.6% 4.1% CVS Health 2.9% 7.4% Hasbro 2.9% 8.1% PepsiCo 2.8% 7.8% Clorox 2.2% 7.6% Starbucks 1.7% 17.6% Walmart 1.5% 2% Apple 0.6% 9... | AbbVie 5% 18.3% See the 10 stocks Stock Advisor returns as of 2/1/20 Selena Maranjian owns shares of AbbVie, Apple, AT&T, Realty Income, Starbucks, and Walt Disney. Among the most promising companies you find, seek the dividend payers among them Look for solid dividend yields Next, look for companies with solid dividen... | See the 10 stocks Stock Advisor returns as of 2/1/20 Selena Maranjian owns shares of AbbVie, Apple, AT&T, Realty Income, Starbucks, and Walt Disney. AbbVie 5% 18.3% So a company with a 1.5% yield may be a better long-term investment than one with a 3% yield, if the former is growing at an average annual rate of 12%, wh... |
24,279 | 2020-12-29 00:00:00 UTC | ACWI, TMO, ABBV, CVX: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/acwi-tmo-abbv-cvx%3A-large-outflows-detected-at-etf-2020-12-29 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI ETF (Symbol: ACWI) where we have detected an approximate $288.6 million dollar outflow -- that's a 2.0% decrease week over week (from 160,000,000 to 156,800,000). Among the... | Among the largest underlying components of ACWI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 1.3%, and Chevron Corporation (Symbol: CVX) is lower by about 0.2%. For a complete list of holdings, visit the ACWI Holdings page » The chart below shows t... | Among the largest underlying components of ACWI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 1.3%, and Chevron Corporation (Symbol: CVX) is lower by about 0.2%. For a complete list of holdings, visit the ACWI Holdings page » The chart below shows t... | Among the largest underlying components of ACWI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 1.3%, and Chevron Corporation (Symbol: CVX) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs c... | Among the largest underlying components of ACWI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 1.3%, and Chevron Corporation (Symbol: CVX) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs c... |
24,280 | 2020-12-29 00:00:00 UTC | Have $600 and 10 Years to Wait? Park It in These 3 Top Stocks | ABBV | https://www.nasdaq.com/articles/have-%24600-and-10-years-to-wait-park-it-in-these-3-top-stocks-2020-12-29 | null | null | Are you in line to receive a $600 stimulus check you don't need right now? If so, you should think about backing that extra cash into one of these top healthcare stocks.
During the coronavirus pandemic, we've seen how successful healthcare companies can thrive during economic circumstances that crush most businesses. A... | The stock offers a juicy 5.2% dividend yield at recent prices, and successful new drug launches put AbbVie in a position to raise its payout significantly over the next decade. AbbVie (NYSE: ABBV), CVS Health (NYSE: CVS), and Teladoc Health (NYSE: TDOC) operate in different corners of the healthcare sector, but they're... | AbbVie (NYSE: ABBV), CVS Health (NYSE: CVS), and Teladoc Health (NYSE: TDOC) operate in different corners of the healthcare sector, but they're all positioned to outperform for patient investors. The stock offers a juicy 5.2% dividend yield at recent prices, and successful new drug launches put AbbVie in a position to ... | AbbVie (NYSE: ABBV), CVS Health (NYSE: CVS), and Teladoc Health (NYSE: TDOC) operate in different corners of the healthcare sector, but they're all positioned to outperform for patient investors. AbbVie This company's doing everything it can to offset competitive pressure for its top-selling immunology drug, Humira. Th... | AbbVie (NYSE: ABBV), CVS Health (NYSE: CVS), and Teladoc Health (NYSE: TDOC) operate in different corners of the healthcare sector, but they're all positioned to outperform for patient investors. AbbVie This company's doing everything it can to offset competitive pressure for its top-selling immunology drug, Humira. Th... |
24,281 | 2020-12-29 00:00:00 UTC | 3 Stocks That'll Turn Your $600 Stimulus Check Into a Money Machine | ABBV | https://www.nasdaq.com/articles/3-stocks-thatll-turn-your-%24600-stimulus-check-into-a-money-machine-2020-12-29 | null | null | More stimulus checks are on the way. After months of political wrangling and plenty of twists and turns, most Americans will soon receive $600 stimulus checks.
For many, this money will be critical in helping make ends meet. For others who aren't struggling financially, it will be a nice bonus they could use in lots of... | Sales also continue to climb for Ubrelvy and Vraylar, two neuroscience drugs AbbVie picked up with its acquisition of Allergan earlier this year. AbbVie AbbVie (NYSE: ABBV) qualifies as a Dividend Aristocrat (an S&P 500 member that has increased its dividends for at least 25 consecutive years) because it was part of Ab... | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Brookfield Renewable Partners L.P., and Innovative Industrial Properties. AbbVie AbbVie (NYSE: ABBV) qualifies as a Dividend Aristocrat (an S&P 500 member that has increased its dividends for at least 25 consecutive y... | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Brookfield Renewable Partners L.P., and Innovative Industrial Properties. AbbVie AbbVie (NYSE: ABBV) qualifies as a Dividend Aristocrat (an S&P 500 member that has increased its dividends for at least 25 consecutive y... | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Brookfield Renewable Partners L.P., and Innovative Industrial Properties. AbbVie AbbVie (NYSE: ABBV) qualifies as a Dividend Aristocrat (an S&P 500 member that has increased its dividends for at least 25 consecutive y... |
24,282 | 2020-12-25 00:00:00 UTC | Got $5,000? These 3 Stocks Are Ridiculously Cheap Right Now | ABBV | https://www.nasdaq.com/articles/got-%245000-these-3-stocks-are-ridiculously-cheap-right-now-2020-12-25 | null | null | You'll find a lot more bargains during post-Christmas sales than you will in the stock market. The major market indexes are at all-time highs. After a fantastic run following the market meltdown earlier this year, valuations are at least a little frothy.
You can still find some stocks available at a discount. If you've... | AbbVie AbbVie (NYSE: ABBV) is one of the least expensive big pharma stocks on the market. The potential for AbbVie's earnings to increase over the next few years is looking pretty good. Many investors focus on the glaring negative for AbbVie: the coming sales decline for Humira. | With improving growth prospects, a fantastic dividend, and a bargain valuation, AbbVie looks like a solid pick for the new year. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Pfizer, and Viatris Inc. AbbVie AbbVie (NYSE: ABBV) is one of the ... | AbbVie AbbVie (NYSE: ABBV) is one of the least expensive big pharma stocks on the market. AbbVie has several other growth drivers as well, including blood cancer drugs Imbruvica and Venclexta, plus antipsychotic drug Vraylar. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of... | With improving growth prospects, a fantastic dividend, and a bargain valuation, AbbVie looks like a solid pick for the new year. AbbVie AbbVie (NYSE: ABBV) is one of the least expensive big pharma stocks on the market. The potential for AbbVie's earnings to increase over the next few years is looking pretty good. |
24,283 | 2020-12-23 00:00:00 UTC | 3 Stocks to Buy With Dividends Yielding More Than 4% | ABBV | https://www.nasdaq.com/articles/3-stocks-to-buy-with-dividends-yielding-more-than-4-2020-12-23 | null | null | Income investors often chase high dividend yields, but their money could be at risk if the yield isn't supported by stable and rising dividends. A company that has the financial clout to pay regular dividends and the right commitment to shareholders should eventually generate solid returns for you, both in terms of div... | ABBV Revenue (TTM = Trailing 12 month) data by YCharts AbbVie has grown rapidly in recent years thanks largely to Humira, its key immunosuppressive drug. Plenty of opportunities for this Dividend Aristocrat AbbVie (NYSE: ABBV) stock is yielding a solid 5% even after its 15% rally so far this year. AbbVie counts as a Di... | Plenty of opportunities for this Dividend Aristocrat AbbVie (NYSE: ABBV) stock is yielding a solid 5% even after its 15% rally so far this year. AbbVie counts as a Dividend Aristocrat given its 49-year streak of annual dividend increases from the time it was part of Abbott. In the third quarter, AbbVie announced a 10.2... | Plenty of opportunities for this Dividend Aristocrat AbbVie (NYSE: ABBV) stock is yielding a solid 5% even after its 15% rally so far this year. AbbVie counts as a Dividend Aristocrat given its 49-year streak of annual dividend increases from the time it was part of Abbott. In the third quarter, AbbVie announced a 10.2... | Plenty of opportunities for this Dividend Aristocrat AbbVie (NYSE: ABBV) stock is yielding a solid 5% even after its 15% rally so far this year. AbbVie counts as a Dividend Aristocrat given its 49-year streak of annual dividend increases from the time it was part of Abbott. In the third quarter, AbbVie announced a 10.2... |
24,284 | 2020-12-23 00:00:00 UTC | AbbVie: FDA Approves IMBRUVICA Prescribing Information Update For Waldenström's Macroglobulinemia | ABBV | https://www.nasdaq.com/articles/abbvie%3A-fda-approves-imbruvica-prescribing-information-update-for-waldenstroms | null | null | (RTTNews) - AbbVie (ABBV) said Wednesday that the U.S. Food and Drug Administration or FDA approved the update of the IMBRUVICA (ibrutinib) Prescribing Information to include efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström's macroglobulinemia (WM).
The approval ... | (RTTNews) - AbbVie (ABBV) said Wednesday that the U.S. Food and Drug Administration or FDA approved the update of the IMBRUVICA (ibrutinib) Prescribing Information to include efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström's macroglobulinemia (WM). "We're encour... | (RTTNews) - AbbVie (ABBV) said Wednesday that the U.S. Food and Drug Administration or FDA approved the update of the IMBRUVICA (ibrutinib) Prescribing Information to include efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström's macroglobulinemia (WM). "We're encour... | (RTTNews) - AbbVie (ABBV) said Wednesday that the U.S. Food and Drug Administration or FDA approved the update of the IMBRUVICA (ibrutinib) Prescribing Information to include efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström's macroglobulinemia (WM). "We're encour... | (RTTNews) - AbbVie (ABBV) said Wednesday that the U.S. Food and Drug Administration or FDA approved the update of the IMBRUVICA (ibrutinib) Prescribing Information to include efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström's macroglobulinemia (WM). "We're encour... |
24,285 | 2020-12-23 00:00:00 UTC | 5 Dividend Stocks Likely to Up Their Yield Soon | ABBV | https://www.nasdaq.com/articles/5-dividend-stocks-likely-to-up-their-yield-soon-2020-12-23 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dividend stocks are a special category of financial assets, providing a lot of benefits for investing that make them attractive for the majority of investors. Searching for dividend stocks to buy, investors will see they offer income and can provide stock p... | People’s United Financial (NASDAQ:PBCT) AbbVie (NYSE:ABBV) Leggett & Platt (NYSE:LEG) AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie is an international healthcare company. ABBV stock has a one-year dividend growth of 19.22%, five-year annual dividend growth of 157.83%, and the years of consecutive dividend... | People’s United Financial (NASDAQ:PBCT) AbbVie (NYSE:ABBV) Leggett & Platt (NYSE:LEG) AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie is an international healthcare company. ABBV stock has a one-year dividend growth of 19.22%, five-year annual dividend growth of 157.83%, and the years of consecutive dividend... | ABBV stock has a one-year dividend growth of 19.22%, five-year annual dividend growth of 157.83%, and the years of consecutive dividend growth are 48. People’s United Financial (NASDAQ:PBCT) AbbVie (NYSE:ABBV) Leggett & Platt (NYSE:LEG) AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie is an international heal... | People’s United Financial (NASDAQ:PBCT) AbbVie (NYSE:ABBV) Leggett & Platt (NYSE:LEG) AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie is an international healthcare company. ABBV stock has a one-year dividend growth of 19.22%, five-year annual dividend growth of 157.83%, and the years of consecutive dividend... |
24,286 | 2020-12-23 00:00:00 UTC | Coronavirus Stimulus Checks: Top Stocks To Buy Now | ABBV | https://www.nasdaq.com/articles/coronavirus-stimulus-checks%3A-top-stocks-to-buy-now-2020-12-23 | null | null | On Monday, Congress approved a coronavirus relief bill that includes $600 stimulus checks for most Americans. Now, investors -- as long as their bills are paid and emergency funds are well-padded -- might be wondering where to spend it. While it might be tempting to drop the cash on a highly risky stock that has a chan... | AbbVie If you're looking for a stock with a formidable dividend yield over 5% as well as considerable prospects for equity growth, AbbVie (NYSE: ABBV) is an excellent choice. If you aren't familiar, AbbVie is a major pharmaceutical company which makes drugs like Humira for autoimmune disorders. 10 stocks we like better... | AbbVie If you're looking for a stock with a formidable dividend yield over 5% as well as considerable prospects for equity growth, AbbVie (NYSE: ABBV) is an excellent choice. If you aren't familiar, AbbVie is a major pharmaceutical company which makes drugs like Humira for autoimmune disorders. 10 stocks we like better... | AbbVie If you're looking for a stock with a formidable dividend yield over 5% as well as considerable prospects for equity growth, AbbVie (NYSE: ABBV) is an excellent choice. If you aren't familiar, AbbVie is a major pharmaceutical company which makes drugs like Humira for autoimmune disorders. 10 stocks we like better... | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Alex Carchidi owns shares of AbbVie. AbbVie If you're looking for a stock with a formidable dividend yield over 5% as well as considerable prospects for equity growth, AbbVie (NYSE: ABBV) is an excellent choice. If you aren't familiar, AbbVie is a major p... |
24,287 | 2020-12-20 00:00:00 UTC | 3 Things to Expect From Berkshire Hathaway in 2021 | ABBV | https://www.nasdaq.com/articles/3-things-to-expect-from-berkshire-hathaway-in-2021-2020-12-20 | null | null | If you're a fan and follower of legendary investor Warren Buffett, then you're certainly aware of Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B). When people talk about mirroring Buffett's buys and sells, they're actually talking about Berkshire's trades. The holdings of the company's portfolio are publicly disclosed e... | During the third quarter, the company added brand new positions in Bristol-Myers Squibb (NYSE: BMY), Merck (NYSE: MRK), and AbbVie (NYSE: ABBV). Around half of Berkshire's $500 billion valuation reflects the value of privately held companies, like See's Candies, Dairy Queen, Helzberg Diamonds, GEICO, Pampered Chef, and... | During the third quarter, the company added brand new positions in Bristol-Myers Squibb (NYSE: BMY), Merck (NYSE: MRK), and AbbVie (NYSE: ABBV). Berkshire's publicly traded investments are called "investments in equity securities" on the company's books, and changes to their value are booked as "investment gains (or lo... | During the third quarter, the company added brand new positions in Bristol-Myers Squibb (NYSE: BMY), Merck (NYSE: MRK), and AbbVie (NYSE: ABBV). You may have seen much different numbers due to gains in the value of the stocks also held by Berkshire during that time, though no amount of unrealized stock gains can fully ... | During the third quarter, the company added brand new positions in Bristol-Myers Squibb (NYSE: BMY), Merck (NYSE: MRK), and AbbVie (NYSE: ABBV). With nearly 1 billion shares worth more than $100 billion, Apple accounts for nearly half of the total value of Berkshire's overall stock holdings. Apple shares have nearly do... |
24,288 | 2020-12-17 00:00:00 UTC | Vanguard High Dividend Yield ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/vanguard-high-dividend-yield-etf-experiences-big-inflow-2020-12-17 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $558.6 million dollar inflow -- that's a 1.8% increase week over week in outstanding units (from 330,453,... | Among the largest underlying components of VYM, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.5%, AbbVie Inc (Symbol: ABBV) is down about 0.4%, and Chevron Corporation (Symbol: CVX) is lower by about 0.8%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year price... | Among the largest underlying components of VYM, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.5%, AbbVie Inc (Symbol: ABBV) is down about 0.4%, and Chevron Corporation (Symbol: CVX) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... | Among the largest underlying components of VYM, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.5%, AbbVie Inc (Symbol: ABBV) is down about 0.4%, and Chevron Corporation (Symbol: CVX) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... | Among the largest underlying components of VYM, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.5%, AbbVie Inc (Symbol: ABBV) is down about 0.4%, and Chevron Corporation (Symbol: CVX) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... |
24,289 | 2020-12-17 00:00:00 UTC | 3 Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-id-buy-right-now-2020-12-17 | null | null | Investors interested in good dividend stocks can have it all. It just takes a little looking when you're bargain hunting, particularly when seeking high dividends that are safe, in stocks that have strong growth potential.
I looked at companies with dividend yields of at least 4% whose balance sheets were not only heal... | Westlake Chemical Partners (NYSE: WLKP), AbbVie (NYSE: ABBV) and SpartanNash (NASDAQ: SPTN) all made the cut. AbbVie continues to be a great dividend play AbbVie's shares are up more than 22% year to date. AbbVie has grown revenue more than 48% over the past five years and through nine months this year, the company is ... | Westlake Chemical Partners (NYSE: WLKP), AbbVie (NYSE: ABBV) and SpartanNash (NASDAQ: SPTN) all made the cut. AbbVie continues to be a great dividend play AbbVie's shares are up more than 22% year to date. AbbVie has grown revenue more than 48% over the past five years and through nine months this year, the company is ... | Westlake Chemical Partners (NYSE: WLKP), AbbVie (NYSE: ABBV) and SpartanNash (NASDAQ: SPTN) all made the cut. AbbVie continues to be a great dividend play AbbVie's shares are up more than 22% year to date. AbbVie has grown revenue more than 48% over the past five years and through nine months this year, the company is ... | Over the past five years, AbbVie has increased its dividend a whopping 128%. Westlake Chemical Partners (NYSE: WLKP), AbbVie (NYSE: ABBV) and SpartanNash (NASDAQ: SPTN) all made the cut. AbbVie continues to be a great dividend play AbbVie's shares are up more than 22% year to date. |
24,290 | 2020-12-12 00:00:00 UTC | 2 High-Yielding Dividend Stocks to Buy if the Market Crashes Again | ABBV | https://www.nasdaq.com/articles/2-high-yielding-dividend-stocks-to-buy-if-the-market-crashes-again-2020-12-12 | null | null | When the markets crashed in March due to concerns surrounding the coronavirus, it happened suddenly and without warning. And while it was a scary ride for many investors, it didn't end up lasting all that long. By April, the Dow Jones was already on the path to recovering, and today it sits at all-time highs. A crash i... | Two stocks you'll want to put on your watchlist in case there is another crash include AbbVie (NYSE: ABBV) and Kraft Heinz (NASDAQ: KHC). AbbVie AbbVie already offers investors a great dividend, paying $1.30 every quarter and yielding 4.9%. When AbbVie's stock crashed along with the markets in March, its share price fe... | AbbVie AbbVie already offers investors a great dividend, paying $1.30 every quarter and yielding 4.9%. When AbbVie's stock crashed along with the markets in March, its share price fell below $65. Two stocks you'll want to put on your watchlist in case there is another crash include AbbVie (NYSE: ABBV) and Kraft Heinz (... | Two stocks you'll want to put on your watchlist in case there is another crash include AbbVie (NYSE: ABBV) and Kraft Heinz (NASDAQ: KHC). AbbVie AbbVie already offers investors a great dividend, paying $1.30 every quarter and yielding 4.9%. When AbbVie's stock crashed along with the markets in March, its share price fe... | AbbVie AbbVie already offers investors a great dividend, paying $1.30 every quarter and yielding 4.9%. When AbbVie's stock crashed along with the markets in March, its share price fell below $65. Two stocks you'll want to put on your watchlist in case there is another crash include AbbVie (NYSE: ABBV) and Kraft Heinz (... |
24,291 | 2020-12-12 00:00:00 UTC | 3 Stocks That Are Giving Their Investors Coal in Their Stockings | ABBV | https://www.nasdaq.com/articles/3-stocks-that-are-giving-their-investors-coal-in-their-stockings-2020-12-12 | null | null | No CEO should be evaluated on their company's stock performance in a single year. Strategies often take several years to play out. When a company's fortunes depend on drug development, the timeline can be even longer. That's why no investor should take it too hard that Galapagos NV (NASDAQ: GLPG), Sage Therapeutics (NA... | Even if the drug were to make it through the regulatory gauntlet, it would face stiff competition from AbbVie's (NYSE: ABBV) Rinvoq, which gained approval in 2019. Spirits were high at that time, as Gilead Sciences (NASDAQ: GILD) had just made a $5.1 billion investment in Galapagos for its research pipeline including f... | Even if the drug were to make it through the regulatory gauntlet, it would face stiff competition from AbbVie's (NYSE: ABBV) Rinvoq, which gained approval in 2019. That's why no investor should take it too hard that Galapagos NV (NASDAQ: GLPG), Sage Therapeutics (NASDAQ: SAGE), and bluebird bio (NASDAQ: BLUE) have had ... | Even if the drug were to make it through the regulatory gauntlet, it would face stiff competition from AbbVie's (NYSE: ABBV) Rinvoq, which gained approval in 2019. That's why no investor should take it too hard that Galapagos NV (NASDAQ: GLPG), Sage Therapeutics (NASDAQ: SAGE), and bluebird bio (NASDAQ: BLUE) have had ... | Even if the drug were to make it through the regulatory gauntlet, it would face stiff competition from AbbVie's (NYSE: ABBV) Rinvoq, which gained approval in 2019. That's why no investor should take it too hard that Galapagos NV (NASDAQ: GLPG), Sage Therapeutics (NASDAQ: SAGE), and bluebird bio (NASDAQ: BLUE) have had ... |
24,292 | 2020-12-11 00:00:00 UTC | AbbVie: CHMP Recommends Approvals Of RINVOQ - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie%3A-chmp-recommends-approvals-of-rinvoq-quick-facts-2020-12-11 | null | null | (RTTNews) - AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ (upadacitinib, 15 mg) for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult patie... | (RTTNews) - AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ (upadacitinib, 15 mg) for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult patie... | (RTTNews) - AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ (upadacitinib, 15 mg) for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult patie... | (RTTNews) - AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ (upadacitinib, 15 mg) for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult patie... | (RTTNews) - AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ (upadacitinib, 15 mg) for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult patie... |
24,293 | 2020-12-10 00:00:00 UTC | AbbVie's Upadacitinib Achieves Superiority Versus Dupilumab In Phase 3b Study On Atopic Dermatitis | ABBV | https://www.nasdaq.com/articles/abbvies-upadacitinib-achieves-superiority-versus-dupilumab-in-phase-3b-study-on-atopic | null | null | (RTTNews) - AbbVie's (ABBV) upadacitinib achieved superiority to dupilumab for the primary and all ranked secondary endpoints, as per a phase 3b head-to-head study in adults with atopic dermatitis.
The safety profile of upadacitinib was consistent with previous atopic dermatitis studies, with no new safety risks observ... | (RTTNews) - AbbVie's (ABBV) upadacitinib achieved superiority to dupilumab for the primary and all ranked secondary endpoints, as per a phase 3b head-to-head study in adults with atopic dermatitis. Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as a once-dail... | (RTTNews) - AbbVie's (ABBV) upadacitinib achieved superiority to dupilumab for the primary and all ranked secondary endpoints, as per a phase 3b head-to-head study in adults with atopic dermatitis. Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as a once-dail... | (RTTNews) - AbbVie's (ABBV) upadacitinib achieved superiority to dupilumab for the primary and all ranked secondary endpoints, as per a phase 3b head-to-head study in adults with atopic dermatitis. Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as a once-dail... | (RTTNews) - AbbVie's (ABBV) upadacitinib achieved superiority to dupilumab for the primary and all ranked secondary endpoints, as per a phase 3b head-to-head study in adults with atopic dermatitis. Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as a once-dail... |
24,294 | 2020-12-10 00:00:00 UTC | Boehringer gets into 'guided-missile drugs' with $1.5 bln deal for NBE | ABBV | https://www.nasdaq.com/articles/boehringer-gets-into-guided-missile-drugs-with-%241.5-bln-deal-for-nbe-2020-12-10 | null | null | By John Miller
ZURICH, Dec 10 (Reuters) - Boehringer Ingelheim is paying 1.18 billion euros ($1.5 billion) for Swiss-based NBE Therapeutics, the German drugmaker said on Thursday, adding pipeline candidates including a drug in early trials against triple-negative breast cancer and lung cancer.
Basel-based biotech NBE, ... | Schlick, now a venture capitalist, in the early 1990s worked with the partnership that eventually led to the development of Humira, AbbVie's ABBV.N drug for auto-immune disorders like psoriasis that is the world's top-selling medicine at about $20 billion annually. Basel-based biotech NBE, in which Boehringer's venture... | Schlick, now a venture capitalist, in the early 1990s worked with the partnership that eventually led to the development of Humira, AbbVie's ABBV.N drug for auto-immune disorders like psoriasis that is the world's top-selling medicine at about $20 billion annually. By John Miller ZURICH, Dec 10 (Reuters) - Boehringer I... | Schlick, now a venture capitalist, in the early 1990s worked with the partnership that eventually led to the development of Humira, AbbVie's ABBV.N drug for auto-immune disorders like psoriasis that is the world's top-selling medicine at about $20 billion annually. By John Miller ZURICH, Dec 10 (Reuters) - Boehringer I... | Schlick, now a venture capitalist, in the early 1990s worked with the partnership that eventually led to the development of Humira, AbbVie's ABBV.N drug for auto-immune disorders like psoriasis that is the world's top-selling medicine at about $20 billion annually. By John Miller ZURICH, Dec 10 (Reuters) - Boehringer I... |
24,295 | 2020-12-10 00:00:00 UTC | The Only Warren Buffett Stock Worth Buying | ABBV | https://www.nasdaq.com/articles/the-only-warren-buffett-stock-worth-buying-2020-12-10 | null | null | Warren Buffett is well known for his investing savvy. He's a particular favorite among long-term buy-and-hold investors who appreciate great companies with stocks at good prices.
Yet as much as Buffett's favorite holding period is forever, the portfolio at Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) that the Oracle ... | Pharmaceutical stocks won big in the third quarter, as Buffett bought shares of Merck (NYSE: MRK), AbbVie (NYSE: ABBV), and Bristol Myers Squibb (NYSE: BMY). Airline stocks got the boot early this year, as Buffett concluded that the coronavirus pandemic had fundamentally and permanently changed the dynamics for passeng... | Pharmaceutical stocks won big in the third quarter, as Buffett bought shares of Merck (NYSE: MRK), AbbVie (NYSE: ABBV), and Bristol Myers Squibb (NYSE: BMY). Berkshire has also made big shifts in its bank stock holdings, selling off stakes in many Wall Street banks while building up its position in favored Bank of Amer... | Pharmaceutical stocks won big in the third quarter, as Buffett bought shares of Merck (NYSE: MRK), AbbVie (NYSE: ABBV), and Bristol Myers Squibb (NYSE: BMY). This is the Buffett stock to buy If you're looking for the true Buffett stock to put in your portfolio, the best choice is Berkshire Hathaway itself. Whether you ... | Pharmaceutical stocks won big in the third quarter, as Buffett bought shares of Merck (NYSE: MRK), AbbVie (NYSE: ABBV), and Bristol Myers Squibb (NYSE: BMY). This is the Buffett stock to buy If you're looking for the true Buffett stock to put in your portfolio, the best choice is Berkshire Hathaway itself. See the 10 s... |
24,296 | 2020-12-10 00:00:00 UTC | 3 Warren Buffett Dividend Stocks You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-warren-buffett-dividend-stocks-you-can-buy-right-now-2020-12-10 | null | null | Warren Buffett has never pushed for his own Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) to initiate a dividend program. He has always maintained that the best ways for Berkshire to reward shareholders are through investing cash in other companies and in Berkshire itself through buybacks.
But don't think for a second... | AbbVie probably won't be a huge growth story in the near term, but it should provide solid total returns over the long run to patient investors. AbbVie Buffett loaded up on big pharma stocks for Berkshire in the third quarter. One of the biggest new positions was AbbVie (NYSE: ABBV). | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Bank of America, Berkshire Hathaway (B shares), and Pfizer. AbbVie Buffett loaded up on big pharma stocks for Berkshire in the third quarter. One of the biggest new positions was AbbVie (NYSE: ABBV). | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Bank of America, Berkshire Hathaway (B shares), and Pfizer. AbbVie Buffett loaded up on big pharma stocks for Berkshire in the third quarter. One of the biggest new positions was AbbVie (NYSE: ABBV). | And, like AbbVie, Pfizer is a great dividend stock. AbbVie Buffett loaded up on big pharma stocks for Berkshire in the third quarter. One of the biggest new positions was AbbVie (NYSE: ABBV). |
24,297 | 2020-12-07 00:00:00 UTC | 7 Medical Marijuana Stocks for a Healthcare Revolution | ABBV | https://www.nasdaq.com/articles/7-medical-marijuana-stocks-for-a-healthcare-revolution-2020-12-07 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
For the past few years, the cannabis sector has been mostly in a bear market. Lately, though, things have been picking up. The supply-demand dynamics have gotten better in Canada and the political situation is turning more favorable in the United States. Th... | Well, let’s take a look: GW Pharmaceuticals (NASDAQ:GWPH) Charlotte’s Web (OTCMKTS:CWBHF) AbbVie (NYSE:ABBV) Aurora Cannabis (NYSE:ACB) Cronos Group (NASDAQ:CRON) Harvest Health & Recreation (OTCMKTS:HRVSF) Aleafia Health (OTCMKTS:ALEAF) Medical Marijuana Stocks to Buy: GW Pharmaceuticals (GWPH) Source: Yarygin / Shutt... | Well, let’s take a look: GW Pharmaceuticals (NASDAQ:GWPH) Charlotte’s Web (OTCMKTS:CWBHF) AbbVie (NYSE:ABBV) Aurora Cannabis (NYSE:ACB) Cronos Group (NASDAQ:CRON) Harvest Health & Recreation (OTCMKTS:HRVSF) Aleafia Health (OTCMKTS:ALEAF) Medical Marijuana Stocks to Buy: GW Pharmaceuticals (GWPH) Source: Yarygin / Shutt... | Well, let’s take a look: GW Pharmaceuticals (NASDAQ:GWPH) Charlotte’s Web (OTCMKTS:CWBHF) AbbVie (NYSE:ABBV) Aurora Cannabis (NYSE:ACB) Cronos Group (NASDAQ:CRON) Harvest Health & Recreation (OTCMKTS:HRVSF) Aleafia Health (OTCMKTS:ALEAF) Medical Marijuana Stocks to Buy: GW Pharmaceuticals (GWPH) Source: Yarygin / Shutt... | Now, this drug is not a big part of ABBV stock’s business. Well, let’s take a look: GW Pharmaceuticals (NASDAQ:GWPH) Charlotte’s Web (OTCMKTS:CWBHF) AbbVie (NYSE:ABBV) Aurora Cannabis (NYSE:ACB) Cronos Group (NASDAQ:CRON) Harvest Health & Recreation (OTCMKTS:HRVSF) Aleafia Health (OTCMKTS:ALEAF) Medical Marijuana Stock... |
24,298 | 2020-12-07 00:00:00 UTC | 7 Cheap Stocks to Buy Before the Market Realizes their Worth | ABBV | https://www.nasdaq.com/articles/7-cheap-stocks-to-buy-before-the-market-realizes-their-worth-2020-12-07 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
No one likes to be the investor who watched a stock soar higher and higher, then bought it in right near the top. That’s one of the worst feelings and once it happens, it can scar investors. Rather than look for the high flyers, it leaves investors looking ... | 7 Auto Stocks to Watch Going Into 2021 With that in mind, let’s look at seven cheap stocks to buy before the market picks up on the value: AbbVie (NYSE:ABBV) Qualcomm (NASDAQ:QCOM) Gogo (NASDAQ:GOGO) Goldman Sachs (NYSE:GS) Nautilus (NYSE:NLS) Ford (NYSE:F) Cheap Stocks to Buy: AbbVie (ABBV) Source: Piotr Swat / Shutte... | Qualcomm (NASDAQ:QCOM) Gogo (NASDAQ:GOGO) Goldman Sachs (NYSE:GS) Nautilus (NYSE:NLS) Ford (NYSE:F) Cheap Stocks to Buy: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Wall Street started realizing AbbVie’s value after its latest earnings report. 7 Auto Stocks to Watch Going Into 2021 With that in mind, let’s look... | Qualcomm (NASDAQ:QCOM) Gogo (NASDAQ:GOGO) Goldman Sachs (NYSE:GS) Nautilus (NYSE:NLS) Ford (NYSE:F) Cheap Stocks to Buy: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Wall Street started realizing AbbVie’s value after its latest earnings report. 7 Auto Stocks to Watch Going Into 2021 With that in mind, let’s look... | Qualcomm (NASDAQ:QCOM) Gogo (NASDAQ:GOGO) Goldman Sachs (NYSE:GS) Nautilus (NYSE:NLS) Ford (NYSE:F) Cheap Stocks to Buy: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com Wall Street started realizing AbbVie’s value after its latest earnings report. 7 Auto Stocks to Watch Going Into 2021 With that in mind, let’s look... |
24,299 | 2020-12-06 00:00:00 UTC | 3 Value Stocks Warren Buffett Owns That You Should Consider Buying Too | ABBV | https://www.nasdaq.com/articles/3-value-stocks-warren-buffett-owns-that-you-should-consider-buying-too-2020-12-06 | null | null | As a young man, Warren Buffett learned from Benjamin Graham, a man who would come to be known as "the father of value investing." Graham wrote the classic book on value investing, The Intelligent Investor. Buffett has called it "the best book about investing ever written."
Thanks in large part to the influence of Benja... | Although Pfizer isn't as cheap as AbbVie and Bristol Myers Squibb, its shares trade at only 12 times expected earnings. AbbVie Berkshire recently loaded up on big pharma stocks, including the purchase of nearly 21.3 million shares of AbbVie (NYSE: ABBV). AbbVie's bargain-bin valuation stems primarily from the looming h... | AbbVie Berkshire recently loaded up on big pharma stocks, including the purchase of nearly 21.3 million shares of AbbVie (NYSE: ABBV). AbbVie's bargain-bin valuation stems primarily from the looming headwinds for its top-selling drug, Humira. However, AbbVie has known for a long time that the day would come when it cou... | AbbVie Berkshire recently loaded up on big pharma stocks, including the purchase of nearly 21.3 million shares of AbbVie (NYSE: ABBV). See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), Bristol Myers Squibb, and Pfizer. AbbVie's bargain-... | See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), Bristol Myers Squibb, and Pfizer. AbbVie Berkshire recently loaded up on big pharma stocks, including the purchase of nearly 21.3 million shares of AbbVie (NYSE: ABBV). AbbVie's bargain-... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.